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This booklet has been updated from the previous versions of the 
Georgia TB Reference Guide and was initially adapted from 
Tuberculosis at a Glance, A Reference Guide for Practitioners 
Covering the Basic Elements of Tuberculosis Care, designed and 
produced by the New York City Department of Health, Bureau of 
Tuberculosis Control.  We gratefully acknowledge permission to 
draw on the content and design of the New York booklet and on 
the Treatment of Latent Tuberculosis Infection handout produced 
by the Charles P. Felton National Tuberculosis Center at Harlem 
Hospital.  We also extend a special thanks to Andi Shane, MD, 
MPH, MSc for updating the childhood tuberculosis section, to 
Jane Tapia, RN and Lisa Sharling, PhD, MPH for editorial 
assistance, and to Dr. Rose-Marie Sales, Tuberculosis Program 
Director, Georgia Department of Public Health, for epidemiology 
and public health consultation. 
  
 




AFB:  Acid-Fast Bacilli 
AIDS:  Acquired Immunodeficiency Syndrome 
ART: Antiretroviral Therapy 
AST: Antimicrobial Susceptibility Testing 
BCG:  Bacillus Calmette-Guerin 
BID: Bis in die (Twice Daily) 
CAP:  Capreomycin 
CBC:  Complete Blood Count 
CNS:  Central Nervous System 
CXR:  Chest X-Ray 
DHT: Delayed-type Hypersensitivity 
DOPT:  Directly Observed Preventive Therapy 
DOT:  Directly Observed Therapy 
EMB:  Ethambutol 
FQN: Fluoroquinolone 
HAART: Highly Active Antiretroviral Therapy 
HCV:  Hepatitis C Virus 
HIV:  Human Immunodeficiency Virus 
IM:  Intramuscular 
INH:  Isoniazid 
IV:  Intravenous 
KM:  Kanamycin 
LFT:  Liver Function Test 
LTBI:  Latent Tuberculosis Infection 
MDR:  Multidrug Resistant 
NRTI:  Nucleoside Reverse Transcriptase Inhibitor 
 
 
NNRTI:  Non-nucleoside Reverse Transcriptase Inhibitor 
PAS:  Para-aminosalicylic Acid 
PI:  Protease Inhibitor 
PO:  Per os (Oral) 
PPD:  Purified Protein Derivative 
PZA:  Pyrazinamide 
RFB:  Rifabutin 
RIF:  Rifampin 
RPT: Rifapentine 
SM:  Streptomycin 
TB:  Tuberculosis 
TST:  Tuberculin Skin Test 
TU:  Tuberculin Unit 
XDR: Extensively Drug-resistant 
  
 
GEORGIA TB REFERENCE GUIDE v 
 
Table of Contents	
I.  Classification System for Tuberculosis ......................................... 1 
II. Epidemiology ............................................................................... 2 
III. Diagnostic Tests for Latent TB Infection .................................... 6 
A.  Tuberculin Skin Test (TST). ................................................... 6 
B. Criteria for a Positive Tuberculin Test, by Risk Group ........... 8 
C. Two-Step Testing and the Booster Reaction ......................... 10 
D. Anergy Testing ...................................................................... 12 
E.  Interferon-γ Release Assays (IGRAs) ................................... 12 
F.  Targeted Testing and Diagnostic Tests for LTBI .................. 16 
G.  Medical Evaluation after Testing for LTBI .......................... 21 
H.  Reporting of Pediatric Positive tests for LTBI ..................... 23 
IV. Treatment of Latent TB Infection (LTBI) ................................. 24 
A. Treatment Regimens ............................................................. 24 
B.  Monitoring of Patients on Treatment for LTBI .................... 33 
C. Contacts of MDR-TB Cases .................................................. 35 
V. Treatment of Current (Active) Disease ...................................... 36 
(Classes III & IV) ............................................................................ 36 
A. Considerations ....................................................................... 36 
B. Standard Daily Therapy for Current (Active) Disease ........... 38 
C. Therapy for Patients with Active TB Disease with Drug 
Resistance or Drug Intolerance .................................................. 44 
 
 
D. Dose Counting ....................................................................... 46 
PAGE INTENTIONALLY LEFT BLANK ............................... 47 
E. Regimen Options for the Preferred Initial Treatment of 
Children and Adults with Tuberculosis ...................................... 53 
F. Drug Resistance ..................................................................... 55 
PAGE INTENTIONALLY LEFT BLANK ............................... 57 
G. Monitoring patients on therapy ............................................. 62 
H. TB and HIV ........................................................................... 66 
I. Antiretroviral Therapy (ART) and Treatment of HIV  
Seropositive Patients with Active Tuberculosis  Disease. .......... 68 
PAGE INTENTIONALLY LEFT BLANK ............................... 75 
J. Paradoxical Reactions or Immune Reconstitution Inflammatory 
Syndrome (IRIS) Associated with Initiation of Antiretroviral 
Therapy During the Course of TB Therapy ............................... 79 
K. Treatment of Extrapulmonary Tuberculosis .......................... 80 
VI.   Pregnancy ................................................................................ 83 
A. Treatment for LTBI and Risk Factors ................................... 83 
B. Treatment of Active TB in Pregnancy ................................... 83 
VII. Childhood Tuberculosis ........................................................... 88 
A. Management Considerations ................................................. 88 
VIII. Tuberculosis and Long Term Care Facilities .......................... 93 
IX. BCG Vaccination ...................................................................... 95 
X. TB Infection Control:  Hospital Isolation Procedures ................ 97 
 
GEORGIA TB REFERENCE GUIDE vii 
 
A.  Administrative Controls ....................................................... 97 
B.  Surveillance for Health Care Workers .................................. 98 
C. Environmental Controls ....................................................... 100 
D. Personal Respiratory Protection .......................................... 100 
XI. Community Tuberculosis Control ........................................... 101 
A.    Reporting Requirements ................................................... 101 
B. Role of the Health Department ............................................ 102 
C. Grady Hospital TB Discharge Policy .................................. 104 
D. The U.S.-Mexico Binational Tuberculosis Referral Program 
(CureTB) .................................................................................. 108 
XII. Georgia Department of Public Health (DPH) Community 
Guidelines for Respiratory Isolation of Patients with Active TB in 
the Community .............................................................................. 110 
XIII.  References ........................................................................... 113 














GEORGIA TB REFERENCE GUIDE 1 
 
I.  Classification System for Tuberculosis 
Class O:  No TB Exposure—Not Infected 
No history of exposure.  Negative reaction to the tuberculin skin 
test.   
 
Class I:  TB Exposure—No Evidence of Infection 
History of exposure (contact to a case of TB) and negative 
reaction to the tuberculin skin test. 
 
Class II:  TB Infection—No Disease 
Positive reaction to the tuberculin skin test, no clinical or 
radiographic evidence of TB, and/or negative bacteriologic studies 
(if done). 
 
Class III:  Current TB Disease 
Clinical, bacteriological, and/or radiographic evidence of current 
tuberculosis.  This is established most definitively by isolation of 
M. tuberculosis.  
 
Class IV:  Previous TB Disease 
History of episode(s) of TB, or abnormal but stable 
radiographicfindings, positive reaction to the tuberculin skin test, 
negative bacteriologic studies (if done) and no clinical or 
radiographic evidence of current disease.  
 
Class V:  TB Suspected 
Diagnosis pending.  Patient should not remain in this category for 
more than three months.  
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II. Epidemiology 
• Worldwide, TB is an enormous global public health problem.  
The World Health Organization (WHO) estimates that there were 
8.7 million new cases of TB disease and more than 1.4 million 
deaths due to TB in 2012.  
 
• TB is the second leading cause of death due to an infectious 
disease (after HIV/AIDS).  TB is also the leading cause of death 
in persons with HIV/AIDS worldwide (although not in the 
United States). 
 
• One-third of the world’s population is infected with and harbors 
Mycobacterium tuberculosis (i.e., latent TB infection) and 
therefore is at risk for developing active disease. 
• The interaction between the TB epidemic and the HIV/AIDS 
epidemic is lethal.  TB adds to the burden of illness of HIV-
infected people and shortens their life expectancy, while the 
HIV epidemic spurs the spread of TB. 
• In the U.S. there was a resurgence of TB from 1985 to 1992.  
The number of cases increased 20% during this time period, 
peaking in 1992 with 26,673 cases reported.  The increased case 
numbers were attributed to the HIV epidemic, decreased 
funding for public health, immigration from countries where TB 
is endemic, and transmission of TB in congregate settings such 
as hospitals, correctional institutions and homeless shelters. 
 
GEORGIA TB REFERENCE GUIDE 3 
 
 
• Due to a number of public health interventions, TB cases began 
declining in 1992 in the U.S.  From 1992 through 2012, there 
has been a 61% decrease in the number of cases, as TB control 
was strengthened nationally.  In 2012, the U.S. reported 9,951 
new TB cases (3.2 per 100,000 population).  The decrease is 
attributed to strengthened public health infrastructure for TB 
prevention and control nationwide.  Concern is rising about a 
new wave of complacency in TB control.  In recent years, 
federal TB control funding has decreased when adjusted for 
inflation. 
• TB is not evenly distributed among the U.S. population.  Cases 
occur disproportionately in urban areas, in conditions of poverty 
and over-crowding, and among racial and ethnic minorities and 
foreign-born persons. In 2012, 63% of the U.S. TB cases 
occurred among foreign-born persons (43% in Georgia). 
• The average lifetime risk of developing active TB following TB 
infection, if no treatment of latent TB infection is received, is 
approximately 10% (5% in the first two years after tuberculin 
skin test conversion [new infection] and 5% in the remaining 
lifetime).  UNAIDS estimates that persons infected with both 
TB and HIV are 30 to 50 times more likely to develop TB 
disease than those infected with TB but who do not have HIV 
infection (10% per year risk  of progression to active TB disease 
among people living with HIV who have LTBI).  
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• Drug resistant TB is a major challenge to global TB control and 
associated with higher morbidity and mortality compared to drug 
susceptible disease. The treatment of highly drug-resistant M. 
tuberculosis requires longer, more complex and expensive 
treatment regimens.  Multidrug-resistant TB (MDR-TB) is 
defined as resistance to at least isoniazid (INH) and rifampin 
(RIF); extensively drug resistant (XDR-TB) is defined as MDR-
TB plus resistance to a fluoroquinolone drug plus an injectable 
drug (kanamycin, amikacin, and/or capreomycin).  Treatment 
regimens are complicated with many potential adverse effects 












Number of TB Cases 
City of Atlanta, Metro Atlanta, Georgia 
1993-2012
City of Atlanta Metro Atlanta Georgia
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• The State of Georgia has had TB rates higher than the U.S. 
average for the last quarter of a century.  In 2012, Georgia had 
359 new TB cases (3.6 per 100,000 population).  Of the culture 
confirmed TB cases tested for drug susceptibility in Georgia in 
2012, 10% had primary resistance to INH, three had primary 
resistance to RIF (1%) and one (0.3%) was MDR.   
• Half (50%) of TB cases in Georgia occurred in four counties 
within the metropolitan Atlanta area in 2012 (DeKalb, 
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III. Diagnostic Tests for Latent TB Infection 
There is no "gold standard" test for latent TB infection (LTBI). Two 
types of diagnostic tests to detect LTBI are now available.  This 
includes the tuberculin skin test (TST) which has been around for 
>100 years and a new generation of diagnostic tests, the interferon-γ 
release assays (IGRAs), which are T-cell based invitro blood tests. 
Two IGRAs are now approved for use by the U.S. FDA. Neither the 
TST nor IGRA tests can distinguish LTBI from active TB disease. 
 
A.  Tuberculin Skin Test (TST).  
The TST measures a delayed type hypersensitivity reaction 
(recruitment of memory T cells to the site of an intradermal injection 
of purified protein derivative [PPD]).  The TST should be carried out 
using the Mantoux method.  Multiple puncture tests (Tine and Heaf) 
should not be used.  Tuberculin skin tests should be administered 
and read by trained healthcare personnel.  The tuberculin skin test 
(TST) is administered by injecting 0.1 ml of 5 tuberculin units (TU) 
of PPD into the dorsal or volar surface of the forearm.  The injection 
is made with a disposable tuberculin syringe, with the needle bevel 
facing upward and placed just under the surface of the skin, so that a 
discrete, pale elevation of the skin (a wheal) 6 mm to 10 mm in 
diameter is produced. 
Needles should not be recapped, purposely bent or broken, removed 
from disposable syringes, or otherwise manipulated by hand.  
Dispose of needles and syringes in puncture-resistant containers.  
Follow standard precautions for infection control. 
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TSTs should be read 48 to 72 hours after administration.  If test 
reading is delayed, a positive reaction may still be measurable up to 
one week after testing.  A test cannot be read as negative if more 
than 72 hours have passed since it was placed.  The transverse 
diameter of palpable induration should be measured and recorded 
in millimeters.  If no induration is present, record “0 mm”.  Do not 
measure erythema (redness). 
 
Limitations of the TST include cross reactions between TST and 
BCG and non-tuberculous mycobacteria. Tuberculin skin testing is 
not contraindicated for persons who have been vaccinated with BCG 
but an advantage of the IGRAs are that they do not cross react with 
BCG (see below).  A positive TST in a BCG-vaccinated person is 
assumed to indicate infection with M. tuberculosis when the person 
tested is at increased risk for recent infection, is from an area with 
high rates of TB, or has medical conditions that increase the risk for 
disease (Section III, B). 
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B. Criteria for a Positive Tuberculin Test, by Risk Group 
Reaction > 5 mm of induration 
• Human immunodeficiency virus (HIV)-seropositive persons 
• Recent contact of an infectious TB case  
• Fibrous changes on chest radiograph consistent with prior TB 
• Patients with organ transplants and other immunosuppressed 
patients (receiving the equivalent of  > 15 mg/d of prednisone 
for 1 month or more including patients who will receive TNF-
α inhibitors) 
Reaction > 10 mm of induration 
• Recent immigrants to the U.S. (within the last 5 years) who 
came from high TB incidence countries 
• Injection drug users 
• Residents and employees of the following high-risk 
congregate settings: prisons and jails, nursing homes, 
hospitals, residential facilities for persons with HIV/AIDS and 
homeless shelters 
• Mycobacteriology laboratory personnel 
• Persons with the following clinical conditions that place them 
at risk of progression from latent TB infection to active TB 
disease: silicosis, diabetes mellitus, chronic renal failure, 
leukemia and lymphoma, carcinoma of the head, neck or lung, 
weight loss of > 10% of ideal body weight, gastrectomy, and 
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jejunoileal bypass  
• Children < 5 yrs of age or infants, children, and adolescents 
exposed to adults at high-risk 
• Recent TST conversion (increase of >10 mm of induration 
within the past 2 years) 
Reaction  > 15 mm of induration  
• Persons with no risk factors for TB 
• Persons who are otherwise at low risk and are tested at the 
start of employment, a reaction of > 15 mm is considered 
positive  
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C. Two-Step Testing and the Booster Reaction 
In some persons (especially individuals > 50 years of age) with 
LTBI, delayed-type hypersensitivity reactions to tuberculin may 
wane over time.  When skin tested years after infection occurred, 
these persons may have a negative tuberculin skin test reaction.  
However, this test may stimulate (boost) their ability to react to 
subsequent tuberculin testing, causing a positive reaction to 
subsequent tuberculin skin tests.  The boosted reaction represents a 
true positive result, but not a true conversion due to recent infection.  
Two-step tuberculin skin testing is used to distinguish between 
boosted reactions and reactions due to new infection. 
 
Two-step testing (at baseline) is recommended for employees or 
residents in institutional settings (such as health care workers or 
correctional institution employees) who will undergo routine, serial 
tuberculin screening (and have not had a TST in the past year), and 
for whom it is important to distinguish between new infection and 
boosted reaction from past infection.  
  
 







1. Place the first test with 0.1 ml (5 TU) of
tuberculin. 
2. If the reaction to the first test is negative, give
a second test with the same dose and strength
of tuberculin, 1-3 weeks later.  (If the reaction
to the first test is positive, consider the person
infected and there is no need for a second
test.) 
3. If the second test is positive, consider the
person infected. 
4. If the second test is negative, consider the
person uninfected. 
5. Individuals who have a positive reaction to
either test require a follow-up evaluation with
chest x-ray.  
6. For individuals who will undergo serial testing
(e.g., annual tuberculin testing), two-step
testing is required for only the first test, to
establish a baseline negative test. Subsequent
tuberculin testing should be only one test. 
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D. Anergy Testing  
Anergy testing is not recommended for routine use in persons 
living with HIV or otherwise immunocompromised.  Factors 
limiting the usefulness of anergy skin testing include problems with 
the standardization and reproducibility, the low risk for TB disease 
associated with a diagnosis of anergy, and the lack of apparent 
benefit of treatment of LTBI for groups of anergic HIV-infected 
persons in the U.S.   
 
E.  Interferon-γ Release Assays (IGRAs) 
Two FDA-approved IGRA tests are commercially available in the 
U.S. These include the QuantiFERON-TB Gold in Tube (QFT) test 
and the TSPOT.TB (TSPOT) test.  Guidelines on this use of these 
IGRAs as diagnostic tests for LTBI have been published by CDC 
[MMWR 2010; 59 (No. RR-5):1-26] but the recommendations are 
not evidence rated.  IGRAs are in-vitro blood tests that are based on 
interferon-γ release (IFN-γ) after stimulation by relatively TB 
specific antigens (e.g., ESAT-6 and CFP-10 in both assays and the 
addition of TB7.7 in QFT).  The QFT is a whole blood assay that 
uses an ELISA technique to measure IFN-γ production. TSPOT uses 
peripheral blood mononuclear cells (PBMCs) and detects (by use of 
ELISPOT) the number of T cells producing IFN-γ.  Because the 
antigens used in the IGRAs are not found in M. bovis BCG (or most 
non-tuberculous mycobacteria), the IGRAs are more specific than 
the TST when used to test persons who have received BCG 
vaccination and do not cross react with most non-tuberculous 
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mycobacteria.  Criteria on what constitutes a positive IGRA test 
have been published and are shown in Tables 1 and 2.  The cut-off 
points are static and there are no criteria for what constitutes an 
IGRA conversion when serial testing is performed.  IGRAs can 
provide a positive, negative, or indeterminate result.  Indeterminate 
results more commonly occur among HIV-seropositive and other 
immunocompromised persons but can occasionally occur among 
healthy individuals.  If the result of the IGRA test is indeterminate, it 
is recommended that the test be repeated.  The risk of developing 
active TB after a positive TST result has been defined in large 
prospective longitudinal studies.  There are limited or no such 
equivalent data for the IGRAs.  Thus far, quantitative results from 
IGRAs (i.e., the degree of positivity) have not been shown to have 
prognostic value in predicting increasing risk of progression to 
active TB and therefore should not be used for that purpose in 
clinical practice.  The IGRAs cost significantly more per test than 
the TST but are logistically easier to perform as they only require a 
single visit. In certain situations or selected populations (e.g., BCG-
vaccinated persons), IGRAs may be cost-effective when taking into 
account cost of chest radiographs avoided compared to the TST 
when cross reactions may be seen.  
14                                                                         GEORGIA TB REFERENCE GUIDE  
Table 1. Interpretation Criteria for the QuantiFERON-TB 
Gold In-Tube Test (QFT-GIT)1 
Interpretation Nil* TB Response† 
Mitogen 
Response§ 
Positive¶ ≤8.0 ≥0.35 IU/ml and ≥25% of Nil Any 
Negative** ≤8.0 <0.35 IU/ml or <25% of Nil ≥0.5 
Indeterminate†† ≤8.0 <0.35 IU/ml or <25% of Nil <0.5 
>8.0 Any Any 
Source: Based on manufacturer recommendations for QuantiFERON-TB 
Gold In-Tube [Package insert]. Available at: 
http://www.cellestis.com/IRM/content/pdf/QuantiFeron%20US%20VerG–
Jan2010%20NO%20TRIMS.pdf. 
* The interferon gamma (IFN-γ) concentration in plasma from blood 
incubated without antigen.  
† The IFN-γ concentration in plasma from blood stimulated with a single 
cocktail of peptides representing early secretory antigenic target-6 (ESAT-6), 
culture filtrate protein-10 (CFP-10), and part of TB 7.7 minus Nil.  
§ The IFN-γ concentration in plasma from blood stimulated with mitogen 
minus Nil.  
¶ Interpretation indicating that Mycobacterium tuberculosis infection is likely.  
** Interpretation indicating that M. tuberculosis infection is not likely.  
†† Interpretation indicating an uncertain likelihood of M. tuberculosis 
infection. 
1From: MMWR 2010;59(RR-5):1-25 
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Table 2. Interpretation Criteria for the T-SPOT.TB 
Test (T-Spot)1  
Interpretation Nil* TB Response† Mitogen§ 
Positive¶ ≤10 spots ≥8 spots Any 
Borderline** ≤10 spots 5, 6, or 7 spots Any 
Negative†† ≤10 spots         ≤4 spots 
Indeterminate** >10 spots Any Any 
≤10 spots <5 spots <20 spots 
Source: Based on Oxford Immunotec Limited. T-Spot.TB [Package insert]. 
Available at: http://www.oxfordimmunotec.com/USpageInsert.\ 
* The number of spots resulting from incubation of PBMCs in culture media 
without antigens.  
† The greater number of spots resulting from stimulation of peripheral blood 
mononuclear cells (PBMCs) with two separate cocktails of peptides representing 
early secretory antigenic target-6 (ESAT-6) or culture filtrate protein-10 (CFP-
10) minus Nil.  
§ The number of spots resulting from stimulation of PBMCs with mitogen 
without adjustment for the number of spots resulting from incubation of PBMCs 
without antigens.  
¶ Interpretation indicating that Mycobacterium tuberculosis infection is likely.  
** Interpretation indicating an uncertain likelihood of M. tuberculosis infection.  
†† Interpretation indicating that M. tuberculosis infection is not likely.  
  1From: MMWR 2010;59(RR-5):1-25 
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F.  Targeted Testing and Diagnostic Tests for LTBI 
Diagnostic testing for LTBI should be targeted at those who are at 
increased risk for having LTBI and in some situations at those who 
if infected with M. tuberculosis are at increased risk of progression 
to active TB disease (see page 17 and Table 3). HIV-infected 
persons with LTBI have the greatest risk of progressing to active TB 
(at rates up to 10% per year).  All persons with HIV-infection 
should undergo testing for LTBI and if LTBI is found should 
strongly be encouraged to initiate and complete treatment for LTBI. 
Patients who take immunomodulating drugs are also at very high 
risk for progression to active TB if infected with M. tuberculosis.  
This includes patients with LTBI who are treated with TNF-α 
inhibitors such as infliximab (Remicade), etanercept (Enbrel), 
adalimumab (Humira), certolizumab pegol (Cimzia), or golimumab 
(Simponi).  Following the initial introduction of TNF-α inhibitor 
drugs there were reports of the subsequent development of 
extrapulmonary and disseminated disease and in some cases death.  
All patients who will be treated with TNF-α inhibitor drugs should 
be screened for LTBI before starting the medication; if found to have 
LTBI, they should be started on therapy for LTBI (after active TB is 
excluded) before starting the TNF-α inhibitor.  Whether treatment 
for LTBI should be completed before a TNF-α inhibitor is started is 
controversial.  Patients preparing to receive a solid organ 
transplant should also be screened for LTBI.  Children less than 5 
years of age are at increased risk for progression to active TB disease 
if infected, but should not be tested for LTBI unless they are at 
increased risk for TB exposure (see page 18).  Persons who recently 
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converted to a positive skin test should be medically evaluated and 
active TB disease ruled out (see section III.G. page 21) and LTBI 
treatment considered.  Although, persons with a chest radiograph 
suggestive of old TB are at increased risk for progression to active 
TB disease they should not be retested for LTBI.    
Who should be targeted for LTBI testing?1 
Diagnostic tests for LTBI are not recommended for people with low 
risk of infection with M. tuberculosis. Certain persons with increased 
risk of developing TB if they have LTBI should be targeted for 
testing.  These include: 
 People who have spent time with someone who has TB 
disease (contacts of active TB cases)  
 People living with HIV or those who have other immune 
compromising illnesses  
 Immigrants from a country where TB disease is common 
(most countries in Latin America, the Caribbean, Africa, 
Asia, Eastern Europe, and Russia)  
 People who live or work somewhere in the United States 
where TB disease is more common (homeless shelters, 
prison or jails, or some nursing homes)  
 People who use illegal drugs 
 People who are preparing to initiate treatment with a TNF-
α inhibitor. 
 People preparing to receive a solid organ transplant. 
1From: MMWR 2010;49(No.RR-6) 
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Testing of low risk individuals for LTBI is discouraged because 
false positive results are more likely to occur in this setting.  Because 
QFT, TSPOT, and TST each measure different aspects of the 
immune response and use different antigens and interpretation 
criteria, test results might not be interchangeable. Different tests can 
yield different results. Studies which employed multiple diagnostic 
tests have demonstrated that discordant test results are not 
uncommon.  
Table 3. High Prevalence and High Risk Groups1 
Groups with a High-
prevalence of Latent TB 
Infection 
Groups with a High Risk of 
Progression to Active TB 
Disease if infected with              
M. tuberculosis 
Persons born in countries with 
high prevalence of TB 
Children less than 5 yr of age 
Persons with HIV coinfection 
Groups with poor access to 
healthcare 
Persons who are close contacts of 
persons with infectious TB 
Persons who live or spend time in 
certain facilities (e.g. nursing 
homes, correctional institutions, 
homeless shelters, drug treatment 
centers) 
Persons whose tuberculin skin test 
results converted to positive in the 
past 1-2 yr 
Persons who have chest 
radiographs suggestive of old TB 
Persons who inject drugs Persons with certain medical 
conditions* 
*Diabetes mellitus, silicosis, prolonged therapy with corticosteroids, 
immunosuppressive therapy particularly TNF-α blockers, leukemia, 
Hodgkin’s disease, head and neck cancers, severe kidney disease, 
certain intestinal conditions, malnutrition 
1From: MMWR 2010;59(RR-5):1-25 
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Which diagnostic test for LTBI should be used? 
 
General Recommendations for Use of Diagnostic Tests for LTBI: 
 CDC guidelines note that either a TST or FDA-approved IGRA 
(i.e. QFT or TSPOT) can be used for diagnostic testing and use 
of either test is an acceptable medical and public health practice.  
As noted below, there are preferences and special 
circumstances in which one of these tests is preferred. 
 CDC guidelines note an IGRA may be used in place of a TST in 
all situations in which they recommend tuberculin skin testing 
as an aid in diagnosing M. tuberculosis infection.  
 
Situations in which an IGRA is preferred but a TST is 
acceptable: 
 Testing of BCG-vaccinated persons (because of improved 
specificity of the IGRA vs. TST in this population) 
 Testing of persons who may be unlikely to return to have the 
TST read (e.g., homeless individuals and injection drug users or 
those with substance abuse) 
Situations in which a TST is preferred but an IGRA is 
acceptable: 
 Testing children aged < 5years (TST is recommended by the 
American Academy of Pediatrics) 
 Serial testing (e.g., health care workers).  While not a CDC 
recommendation, we recommend that the TST be used for serial 
testing programs.  Recent reports have indicated very high rates 
of diagnostic test "conversion" (e.g., up to 10-fold higher than 
the TST) when IGRAs were used for serial testing of health care 
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workers in low risk/low prevalence situations (thus suggesting 
the IGRA results were false positive).  In addition, the Canadian 
Tuberculosis Committee has concluded that there is insufficient 
published evidence to recommend serial IGRA testing in health 
care workers and other populations. 
Situations in which a TST or IGRA may be used without 
preference:  
 Contact investigations (i.e., testing of recent contacts of persons 
known or suspected to have active TB).  
 
Situations in which testing with both an IGRA and a TST may be 
considered: 
 When additional evidence of infection is required to encourage 
a person that they have LTBI and should take and adhere to 
therapy for LTBI (e.g., foreign born health care worker who 
believes that their positive TST result is attributable to BCG) 
 When the initial diagnostic test performed in a healthy person at 
low risk for both infection and progression is positive (and 
thought to be a false positive).  This situation could be 
prevented by using targeted testing and not testing low risk 
individuals. 
 Repeating an IGRA or performing a TST might be useful when 
the initial IGRA result is indeterminate, borderline, or invalid 
and a reason for testing persists. 
 In very high risk individuals when missing the presence of 
LTBI could have serious consequences (e.g., individuals to be 
started on TNF-α blockers or other immunocompromising 
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medications). 
G.  Medical Evaluation after Testing for LTBI 
 Neither an IGRA nor a TST can distinguish LTBI from 
active TB disease.  A negative IGRA or TST does not rule out 
active TB disease. 
 
 Persons with a positive TST or IGRA should be evaluated for 
the likelihood of M. tuberculosis infection, for risks for 
progression to active TB if infected and for symptoms and signs 
of active TB.   
 
 A diagnosis of LTBI requires that active TB be excluded by 
medical evaluation which should include taking a medical 
history and a physical exam to check for suggestive symptoms 
and signs, a chest x-ray, and when indicated, testing of sputum 
or other clinical samples for the presence of M. tuberculosis.   
 
 Persons with a newly documented diagnostic test for LTBI 
(positive TST or IGRA) should have a chest x-ray performed to 
ensure that they do not have active TB disease.  After an initial 
negative chest x-ray, no routine follow-up chest x-rays are 
necessary.  Persons with a positive diagnostic test for LTBI 
should be educated about the signs and symptoms of active TB 
disease and instructed to consult with a physician if these 
symptoms occur. 
 
 In healthy persons who have a low likelihood both of M. 
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tuberculosis infection and of progression to active TB disease if 
infected, a single positive IGRA or TST result should not be 
taken as reliable evidence of M. tuberculosis infection. Because 
of the low probability of infection, a false-positive result is 
more likely. In such situations, the likelihood of M. tuberculosis 
infection and of disease progression should be reassessed, and 
the initial test results should be confirmed. Repeat testing, with 
either the initial test or a different test, may be considered on a 
case-by-case basis. For such persons, an alternative is to 
assume, without additional testing, that the initial result is a 
false positive. This becomes somewhat complex because of the 
lack of a "gold standard" diagnostic test for LTBI.  For healthy 
persons who have a low risk for both infection and progression, 
discounting an isolated positive result as a false positive may be 
reasonable. This will increase detection specificity and decrease 
unnecessary treatment. 
 
 In persons with discordant test results (i.e., one positive and 
the other negative), decisions about medical or public health 
management require individualized judgment in assessing the 
quality and magnitude of each test result (e.g., size of induration 
and presence of blistering for a TST; and the TB Response, Nil, 
and Mitogen values for an IGRA), the probability of infection, 
the risk for disease if infected, and the risk for a poor outcome if 
disease occurs.  Patients who are at high risk for progression to 
active TB when LTBI is present (e.g., HIV-infected persons, 
those scheduled to begin a TNF-α inhibitor, children < 5 years) 
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should be assumed to have LTBI if one diagnostic test is 
positive (even if there are discordant results).  For persons who 
have received BCG and who are not at increased risk for a poor 
outcome if infected, TST reactions of <15 mm in size may 
reasonably be discounted as false positives when an IGRA is 
clearly negative.  In other situations, inadequate evidence exists 
on which to base recommendations for dealing with discordant 
results. Consultation with a TB expert should be considered 
when discordant results are present.   
 
 Persons with a positive diagnostic test for LTBI who have 
active TB excluded, should be considered for treatment of 
LTBI.  Treatment of LTBI is recommended for those at 
increased risk of progression to active TB disease (see Table 3).  
Treatment regimens for LTBI are described below.   
 
H.  Reporting of Pediatric Positive tests for LTBI 
Latent TB infection (LTBI) in children indicates recent transmission 
of TB in the community.  Also, young children who are infected 
with TB are at high risk of progressing to TB disease.  Because of 
the extreme importance of identifying children who have been 
exposed to and infected with TB, LTBI in a child less than 5 years 
old is a notifiable disease in the state of Georgia.  Cases may be 
reported electronically at http://sendss.state.ga.us, by calling 1-866-
782-4584, or by calling your local health department. 
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IV. Treatment of Latent TB Infection (LTBI) 
Treatment of LTBI is recommended for patients at increased risk for 
developing active TB disease.  Those at increase risk for developing 
active TB disease following infection with M. tuberculosis include 
HIV-infected persons, those receiving immunosuppressive therapy 
(or scheduled to receive immunosuppressive therapy including TNF-
α inhibitors), children <5 years old, those with diabetes or chronic 
renal failure on hemodialysis, close contacts of patients with recent 
pulmonary TB, or those who have converted from a negative to a 
positive diagnostic test for LTBI (TST or IGRA) within the previous 
2 years.  The risk of serious disease, including miliary or 
disseminated TB and tuberculous meningitis, is highest among 
patients with HIV infection. Infants, the elderly, and patients with 
other causes of severe immunosuppression are also at increased risk. 
Treatment for LTBI should be started only if clinical and 
radiographic evaluations exclude active TB disease. Persons with 
LTBI who are considered to be at high risk for developing active TB 
should be offered (and encouraged to take) treatment for LTBI 
irrespective of age.  
 
A. Treatment Regimens 
Treatment regimens for LTBI are outlined in Table 4.  Several 
different regimens are recommended by the CDC and American 
Thoracic Society (ATS).  These include: 
1.  Isoniazid (INH). INH for 9 months is standard therapy for the 
treatment of LTBI in adults and is the preferred treatment for LTBI 
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among children <12 years of age (due to presumed infection with a 
drug susceptible isolate).  A six month regimen of INH is an 
alternative regimen in HIV-seronegative adults.   
2.  Rifampin.  Rifampin for 4 months (6 months in children) is an 
alternative regimen for the treatment of LTBI (e.g., among persons 
infected with INH-resistant strains) and may also be used as an 
alternative regimen for persons presumed to be infected with a drug-
susceptible (i.e., INH-susceptible) strain.  The efficacy of this shorter 
regimen compared to 9 months of isoniazid has not been established, 
but it has improved adherence and may have fewer adverse effects 
3.  INH plus Rifapentine (RPT).  A short course regimen of weekly 
INH plus rifapentine for 12 weekly doses (given by directly 
observed therapy [DOT]) has recently been recommended as an 
equal alternative to 9 months of INH for treatment of LTBI for 
adults and children >12 years of age, including HIV-infected patients 
not taking antiretrovirals. This regimen is NOT recommended for 
HIV-infected persons taking antiretroviral drugs, pregnant women 
(or those expecting to become pregnant), children <2 years old, or 
patients infected with suspected INH-resistant, rifampin-resistant or 
MDR isolates.   
Because of the marked increase risk of hepatotoxicity (compared to 
INH or rifampin alone), rifampin plus pyrazinamide [2 month short 
course regimen] is NOT recommended for the treatment of LTBI 
although these drugs remain an important component of a multidrug 
regimen in the treatment of active TB disease.
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USPHS/IDSA EVIDENCE BASED RATING 
SYSTEM FOR THE STRENGTH OF TREATMENT 
RECOMMENDATIONS AND QUALITY OF 
EVIDENCE 
 
Strength of the recommendation 
 
A. Preferred; should generally be offered 
B. Alternate; acceptable to offer 
C. Offer when preferred or alternative regimens cannot be 
given 
D. Should generally not be offered 
E. Should never be given 
 
 
Quality of evidence supporting the recommendations 
 
I. At least one randomized trial with clinical end points 
II. Clinical trials that either are not randomized or were 
conducted in other populations 
III. Expert opinion 
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Table 4. Summary of LTBI Treatment Guidelines1 


















Rifampin 4 mo  Daily 
 






















1Adapted from: MMWR 2003;52: 735-739 and MMWR 2011;60: 1650-3. 
*Our Recommendation is DO NOT USE rifampin-
pyrazinamide (RIF-PZA) for LTBI 
 
Recommended regimens, dosages, length of therapy and number of 
doses for LTBI therapy are listed in Tables 5 and 6 on pages 28 – 31. 
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Table 5.  Treatment of LTBI – Recommended Drug  
Drug 
Interval and 







for 9 months 
 
Daily DOT for 
 9 months  
 
Twice-weekly 
DOT for 9 
months 
300 mg PO 
(5 mg/kg - Maximum Dose 300 mg) 
 
300 mg PO 
(5 mg/kg - Maximum Dose 300 mg) 
 
900 mg PO 
(15 mg/kg - Maximum Dose 900 mg) 
270 doses 
 within 12 
months 
190 doses  
within 12 
months 







for 4 months  
(18 weeks) 
Daily DOT for 4 
months  
(18 weeks)  
600 mg PO 
(10 mg/kg - Maximum Dose 600 mg) 
 
600 mg PO 
(10 mg/kg - Maximum Dose 600 mg) 
120 doses  
within 6 
months 







Once weekly by 




15 mg/kg PO (rounded up to the 
nearest 50 or 100 mg); 
900 mg PO maximum 
Rifapentine: 
10.0-14.0 kg 300 mg PO 
14.1-25.0kg 450 mg PO 
25.1-32.0 kg 600 mg PO 
32.1-49.9 kg 750 mg PO 










* Pyridoxine (Vitamin B6) 25 – 50 mg is recommended to be given with each dose of INH 
(in patients with normal renal function) as a preventive measure against INH-induced 
peripheral neuropathy.  ** Daily self-administered = 7 days/week   Daily DOT = 5 
days/week (Monday through Friday) 
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LTBI Treatment Regimens for Adults (>16 years of age) 
Comments 
In HIV-infected persons, INH may be taken concurrently with antiretroviral agents 
including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), protease inhibitors, or integrase inhibitors. 
If twice-weekly dosing is used for INH, it must be given by DOT.  The twice weekly 
regimen of INH for treatment of LTBI is NOT recommended for HIV-infected persons 
with LTBI. 
 
Once weekly dosing of INH plus rifapentine must be given by DOT.  
 
Pyridoxine is recommended for those taking INH to prevent INH-induced 
peripheral neuropathy. 
 
Rifampin is recommended for the treatment of LTBI in persons who are contacts of TB 
cases with proven or suspected INH-resistant, rifampin susceptible TB but may also be 
used in other persons with LTBI (e.g., contacts on drug susceptible TB cases and 
unknown contacts when rifampin resistant or MDR-TB is not suspected). 
 
INH and RPT is recommended as an equal alternative to 9 months of daily self-
administered INH for treating LTBI in otherwise healthy persons (12 years and older) at 
high risk for developing active TB. This includes close contacts of active TB cases, 
recent converters, HIV-infected persons NOT on antiretroviral agents, and persons with 
old healed TB on chest x-ray. 
INH and RPT may also be used in situations where it offers practical advantages or for 
individuals unlikely to complete 9 months of daily INH. 
INH and RPT is NOT recommended for the following groups: children aged <2 years, 
because the safety and pharmacokinetics of RPT have not been established; HIV-
infected patients receiving antiretroviral treatment, because the drug interactions have 
not been studied; pregnant women or women expecting to become pregnant during 
treatment, because safety in pregnancy is unknown; and patients who have LTBI with 
presumed INH or RIF resistance or MDR resistance.  
adm = administered; MDR = multidrug resistant (resistance to at least both INH and RIF) 
NOTE:  Isoniazid is available in 100 and 300 mg tablets (both are scored for dividing in 
half (½).  Rifapentine is available in 150 mg tablets only. 
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Table 6.  Treatment of LTBI - Recommended Drugs  






Daily self-adm** for 9 
months (39 weeks) 
Daily DOT for 9 months  
(39 weeks) 
Twice-Weekly DOT for 9 
months (39 weeks) 
10-15 mg/kg PO 
(Maximum Dose 300mg) 
10-15 mg/kg PO 
(Maximum Dose 300mg)  
20-30 mg/kg PO 
(Maximum Dose 900mg)  
270 doses within 
12 months 
190 doses within 
12 months 
76 doses within 
12 months 
Rifampin Daily self-adm** for 6 
months  (26 weeks) 
Daily DOT for 6 months  
(26 weeks) 
10-20 mg/kg PO 
(Maximum Dose 600mg)  
10-20 mg/kg PO 
(Maximum Dose 600mg)  
180 doses within 
9 months 
130 doses  





Once weekly by DOT for 12 
doses (12 weeks) 
Isoniazid: 
15 mg/kg PO rounded up 
to the nearest 50 or 100 
mg; 
900 mg PO maximum 
Rifapentine: 
10.0-14.0 kg 300 mg PO 
14.1-25.0kg 450 mg PO 
25.1-32.0 kg 600 mg PO 
32.1-49.9 kg 750 mg PO 
Equal to or over 50.0 kg 
900 mg (Maximum dose) 
PO 
11 doses within 
16 weeks (doses 
may be given no 
more frequently 
than every 72 
hours) 
adm = administered;  MDR = multidrug resistant (resistance to at least both INH and RIF) 
* Pyridoxine (Vitamin B6) 25 mg is recommended to be given with each dose of INH 
(in patients with normal renal function) to prevent INH-induced peripheral 
neuropathy. **Daily self administrated (adm) = 7 days/week;  Daily DOPT = 5 
days/week (Monday through Friday).      
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Regimens for Children (from birth through 15 years) 
Comments 
Isoniazid for 9 months is the preferred regimen for children < 12 years of age. 
 
DOT must be used with twice-weekly dosing.The twice weekly regimen of INH for 
treatment of LTBI is NOT recommended for HIV-infected persons. 
 
* Pyridoxine (Vitamin B6) 25 mg is recommended to be given with each dose of INH (in 
patients with normal renal function) to prevent INH-induced peripheral neuropathy.   
Rifampin is recommended for the treatment of LTBI in persons who are contacts of TB 
cases with proven or suspected INH-resistant, rifampin susceptible TB but may also be 
used in other persons with LTBI (e.g. INH susceptible contacts, unknown contacts when 
rifampin resistant or MDR-TB is not suspected).  INH is preferred therapy for LTBI in 
children < 12 years of age when INH resistance in the source patient is not suspected. 
INH and RPT is recommended as an equal alternative to 9 months of daily self-
administered INH for treating LTBI in otherwise healthy persons (>12 years of age) at 
high risk for developing active TB. This includes close contacts of active TB cases, 
recent converters, HIV-infected persons NOT on antiretroviral agents, and persons with 
old healed TB on chest x-ray. 
The INH-RPT regimen is not recommended by CDC for use in children <12 years of 
age. Consult with a TB expert if this regimen is considered for use in the treatment of 
LTBI for children aged 2 through 11 years of age who are close contacts for whom the 
INH and RPT regimen may be considered because it offers practical advantages or 
because the child is unlikely to complete 9 mo of daily INH. 
INH and RPT should NOT recommended for the following patients:  children age <2 
years; HIV infected persons receiving antiretroviral treatment; pregnant women or 
women expecting to become pregnant during treatment; and patients who have LTBI 
with presumed INH or RIF resistance or multidrug resistance (MDR).   
NOTE 1: INH is available in 100 and 300 mg tablets (both are scored for dividing in half 
(½).  Rifapentine is available in 150 mg tablets only. NOTE 2: Directly Observed 
Therapy (DOT) is required for all children with LTBI <5 years of age and those 
receiving ANY intermittent dosing regimen. Directly Observed Therapy (DOT) is 
recommended for all children up to the age of 15 years.   
NOTE 3:  One month is 4.3 weeks. 
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Table 7.  LTBI Treatment Drug Adverse Reactions  








effects on central 
nervous system, 
drug interactions 
Baseline measurements of 
AST for adults. 
Repeat measurements if: 
* baseline results are 
abnormal 
* client is at high-risk for 
adverse reactions 
* client has symptoms of 
adverse reactions 
Hepatitis risk increases 
with age and alcohol 
consumption. 






















Complete blood count, 
platelets and liver function 
tests. 
Repeat measurements if: 
* baseline results are 
abnormal 
* client has symptoms of 
adverse reactions 
Prior to starting RIF or 
RPT: need to carefully 
review all medications 
being taken by the patient 
with LTBI and ensure there 
is no contraindication to 
the use of that medication 
and RIF or RPT. 
Hepatitis risk increases 
with age and alcohol 
consumption. Rifampin 
monotherapy may be 
associated with lower risk 
of hepatotoxicity compared 
to INH monotherapy for 
patients being treated for 
LTBI. 
Need to carefully review for 
possible drug-drug 
interactions prior to starting 
RIF or RPT and ensure 
there are no 
contraindications to these 
agents prior to using them 
for the treatment of LTBI.   
* Hypersensitivity reaction to rifamycins (rifampin or rifapentine): reactions may include a 
flu like syndrome (e.g. fever, chills, headaches, dizziness, musculoskeletal pain), 
thrombocytopenia, shortness of breath or other signs and symptoms including wheezing, 
acute bronchospasm, urticaria, petechiae, purpura, pruritus, conjunctivitis, angioedema, 
hypotension or shock. If moderate to severe reaction (e.g. thrombocytopenia, 
hypotension), hospitalization or life-threatening event: Discontinue treatment. If mild 
reaction (e.g. rash, dizziness, fever): Continue to monitor patient closely with a low 
threshold for discontinuing treatment.  
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B.  Monitoring of Patients on Treatment for LTBI 
For all patients:   
• Initial clinical evaluation and baseline ALT (or AST) on all adult 
patients who will be receiving treatment for LTBI 
• Follow-up clinical evaluations at least monthly if receiving INH 
or RIF alone; for those on self-administered therapy, never 
dispense more than one month of therapy (and no refills) 
• Include careful questioning about side effects and a brief physical 
examination checking for evidence of hepatitis or other side 
effects 
• Educate patients about side effects associated with LTBI treatment 
(see Table 7) 
• Advise patients to stop treatment and promptly seek medical 
evaluation if adverse effects shown in Table 7 occur. 
• If side effects occur, evaluate promptly and change (i.e., 
discontinue) treatment if indicated 
•  CDC guidelines state routine monthly monitoring of hepatic 
enzymes (“liver function tests”) are not generally indicated with 
INH or RIF-only treatment unless risk factors present for increase 
risk of hepatotoxicity.  We recommend baseline liver function 
tests (LFTs) in all adults prior to initiating treatment for LTBI.  
Consider monthly ALT (or AST testing) in adults.   
• In the absence of liver disease or HIV infection, children on LTBI 
do not need monthly ALT (or AST) monitoring. 
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Indications for regular monthly monitoring of LFTs: 
• Abnormal ALT (or AST) at baseline 
• HIV infection 
• Pregnancy 
• First three months postpartum 
• Chronic liver disease (including HCV infection) 
• Regular alcohol use 
• Patients on other drugs which are potentially hepatotoxic 
• Advanced age 
Medication should be discontinued and patient evaluated if: 
• Transaminase levels > 3 times upper limit of test in presence 
of symptoms of adverse events 
• Transaminase levels > 5 times upper limit of test in 
asymptomatic patient 
Pyridoxine (Vitamin B6) should be used (25-50 mg/day) with INH 
for persons with conditions in which neuropathy is common (e.g., 
HIV, diabetes, alcoholism, malnutrition) as well as pregnant women 
and persons with a seizure disorder to prevent isoniazid-associated 
neuropathy.  It should be given to all HIV-infected persons, all 
children, and women who are breastfeeding.  For healthy individuals 
on a normal diet, pyridoxine is optional.  However, we prefer to give 
pyridoxine to all patients on INH. Pyridoxine (at 25 mg per day) is 
also recommended for children on INH. 
  
 
GEORGIA TB REFERENCE GUIDE 35 
 
C. Contacts of MDR-TB Cases (i.e., cases resistant to at least 
isoniazid and rifampin) 
In deciding how to treat persons with latent TB infection which may 
be due to infection with a MDR-TB strain, the following four 
questions should be considered.  A TB specialist should be 
consulted in the management of contacts to MDR-TB cases. 
 
• How likely is it that a patient is newly TB infected?  A patient 
with a documented positive prior TST (or other diagnostic test 
such as an IGRA) is much less likely to be newly infected. 
• How likely is it that the patient is infected with an MDR-TB 
strain?  An infant with a positive diagnostic test for LTBI (TST 
or IGRA) whose parent has active MDR-TB is highly likely to be 
infected with MDR-TB.  In contrast, a health care worker with a 
positive TST and no known source case may have a low 
probability of being MDR-TB infected. 
• How likely is the patient to develop active TB? Those at highest 
risk include infants and persons who are HIV infected or 
otherwise immunocompromised.  
• What is the drug-susceptibility pattern of the source patient’s 
isolate? Treatment of LTBI must be tailored to the susceptibility 
pattern of the source patient’s isolate.  When the source patient is 
known to have isoniazid-resistant TB, rifampin may be used for 
treatment of LTBI.  There are no evidence-based guidelines for 
the treatment of LTBI when an individual is thought to be infected 
with a MDR-TB strain.  In some cases of MDR-TB or XDR-TB, 
no LTBI regimen is available.  
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V. Treatment of Current (Active) Disease  
 (Classes III & IV)  
A. Considerations 
1) The provider (or public health program if this is the site of 
treatment) is responsible for prescribing an appropriate treatment 
regimen and ensuring that treatment is completed successfully.  It is 
strongly recommended that TB treatment be undertaken in 
consultation with a physician who is well versed and experienced in 
its management. 
2) In general, initiate therapy with a four drug regimen (INH, 
RIF, PZA, EMB) as described on pages 40-58 (Tables 8 and 10). A 
number of different treatment options are available as outlined in 
Tables 8 and 10 and discussed in further detail below. 
3) DIRECTLY OBSERVED THERAPY (DOT) IS THE 
STANDARD OF CARE FOR ALL PATIENTS WITH ACTIVE 
TUBERCULOSIS DISEASE TO FACILITATE ADHERENCE 
AND COMPLETION OF THERAPY.  DOT can be given by the 
patient’s local county public health department.  
Patient-centered care (also called enhanced DOT) is encouraged for 
all patients.  Treatment is tailored and supervised based on each 
patient’s clinical and social circumstances.  TB treatment is most 
successful within a comprehensive framework that addresses both 
clinical and social issues of relevance to the patient. 
4) Drug susceptibility testing should be performed on initial M. 
tuberculosis isolates in ALL cases.  Drug susceptibility testing and 
AFB cultures are performed by the Georgia Public Health 
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Laboratory (Phone: 404-327-7944 or 404-327-7945). Repeat 
susceptibility testing should be performed on M. tuberculosis 
isolates for patients who do not respond to therapy or who have a 
positive culture after two months of therapy. 
5) The best way to measure the effectiveness of therapy for 
pulmonary TB is to monitor patients bacteriologically through 
sputum examination at least monthly until two consecutive negative 
cultures are obtained. We recommend obtaining monthly sputum 
examinations throughout the course of therapy. For patients with 
pulmonary TB, it is essential to obtain a sputum culture after 
two months of therapy.    
Patients with drug-susceptible cavitary pulmonary TB who have a 
positive sputum culture after two months of therapy are at increased 
risk for relapse after six months of therapy; a positive culture after 
two months of therapy impacts recommendations for the total length 
of therapy.  Patients being treated for uncomplicated pulmonary TB 
do not require frequent chest x-rays; bacteriologic examination is far 
more important than monitoring chest films. 
6) If a patient’s sputum cultures remain positive beyond two months 
of therapy, the possibility of drug-resistant disease, malabsorption, 
or patient failure to take medications as prescribed should be 
considered.  Drug susceptibility studies should be repeated, and if 
not already on directly observed therapy (DOT), such patients 
should be placed on DOT. 
7) Adjust weight-based doses as weight changes. 
8) For patients with drug susceptible pulmonary tuberculosis, 
treatment should be extended from 6 months to 9 months for 
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patients who have cavitary disease on their initial CXR and a 
positive sputum culture after 2 months of therapy. 
9) A treatment algorithm for TB is shown in Figure 1, on page. 42. 
 
B. Standard Daily Therapy for Current (Active) Disease 
All patients should initially be started on a 4-drug regimen 
(INH, RIF, PZA, EMB) unless there are contraindications to 
any of the drugs or the patient is pregnant (pregnant patients may 
be started on a 3- or 4-drug regimen based on certain circumstances 
which are discussed further on page 93).  See Tables 10 and Tables 
11- 14 on pages 47-52 for dosing recommendations for adults and 
children. 
Treatment regimens are listed in Table 8, page 40.  Therapy for 
active TB disease consists of an initiation phase and a 
continuation phase.   
The initiation phase generally consists of a 4-drug regimen given 
daily or 5 times per week per DOT. An option for twice weekly 
therapy after the initial 2 weeks of daily therapy (“Denver 
regimen”) also exists: this option should NOT be used for patients 
with HIV infection, cavitary pulmonary TB, disseminated TB, 
vertebral TB or for patients who have co-morbid medical conditions 
such as diabetes mellitus, end-stage renal disease or liver disease.  
An intermittent regimen should NEVER be used in the initiation 
phase for the treatment if patients with HIV infection.  
The initiation phase is followed by a continuation phase. For drug 
susceptible disease, this can consist of daily, 5 times per week, 
thrice weekly or twice weekly therapy by DOT (see Table 8).  For 
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patients with HIV co-infection, in the continuation phase, twice 
weekly therapy is contraindicated because of increased risk of 
relapse with rifampin-resistant disease; in such cases therapy should 
be given daily (or 5 times per week) or thrice weekly by DOT. See 
Figure 1, page 42. 
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Table 8. Recommended Regimens for Treatment of Adults and Children with 





Initial Phase Continuation Phase 
Comments 
Drugs 
Interval & Dose # 
(minimal duration) Drugs 
Interval & Dose # 
(minimal duration) 




Daily DOT for 40 












1a. Daily DOT for 90      
doses (18 wks) 
OR 
1b. Twice-weekly DOT 
for 36 doses (18 wks) 
OR 
1c. Thrice-weekly DOT 
for 54 doses (18wks) 
OR 
1d. Once weekly for 18 
doses (18 wks) 




(EMB) until susceptibility to 
isoniazid (INH) and 
rifampin (RIF) is 
demonstrated. 
 




Daily DOT for 10 
doses (2 wks), 
then twice-weekly 







2a. Twice-weekly DOT 
for 36 doses (18 wks) 
OR 
2b. Once weekly for 18 
doses (18 wks) 
Regimen must be directly 
observed. Include EMB in 
the initial phase. After the 
initial phase, continue EMB 
until susceptibility to INH 
and RIF is demonstrated.  
Do NOT use this regimen 
for HIV-infected patients* 
NOTE: Daily DOT = 5 days/week (Monday through Friday). Self-administered doses (including those on weekends) 
will not be counted toward the total doses. 
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NOTE:  Pyridoxine (Vitamin B6) 25- 50 mg/daily should be added to all regimens to prevent the development of INH-
induced peripheral neuropathy. 
^NOTE: Duration of therapy should be extended to 9 months (31 weeks continuation phase, 39 weeks total) for patients 
who have cavitary pulmonary TB and remain sputum culture positive after 2 months of therapy.  Some experts would 
extend therapy to 9 months for all patients with HIV/TB, especially those slow to convert to negative cultures or not on 
effective HIV treatment.   
*NOTE:  Option 2 should NOT be used for patients with HIV infection, cavitary pulmonary TB, disseminated TB, 
vertebral TB or for patients who have co-morbid medical conditions such as diabetes mellitus, end-stage renal 
disease or liver disease. 
 NOTE:  Options 1d and 2b should be used only in HIV-seronegative adult patients who have negative sputum 
smears at the time of completion of 2 months of therapy and who do not have cavitation on the initial chest 
radiograph.  For patients started on this regimen and found to have a positive culture from the 2-month 
specimen, treatment should be extended an extra 3 months.  
NOTE:  Split dosing should be avoided. 
NOTE:  Refer to current drug reference or drug package insert for a complete list of adverse drug reactions and 
drug interaction 
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Patients in whom tuberculosis is proven or strongly suspected should have treatment initiated with 
isoniazid, rifampin, pyrazinamide, and ethambutol for the initial 2 months.  A repeat smear and 
culture should be performed when 2 months of treatment has been completed.  If cavities were 
seen on the initial chest radiograph or the acid-fast smear is positive at completion of 2 months of 
treatment, the continuation phase of treatment should consist of isoniazid and rifampin daily or 
twice weekly for 4 months to complete a total of 6 months of treatment.  If cavitation was present on 
the initial chest radiograph and the culture at the time of completions of 2 months of therapy is 
positive, the continuation phase should be lengthened to 7 months (total of 9 months treatment).  If 
the patient has HIV infection and the CD4+ cell count is <100/µl, the continuation phase should 
consist of daily or three times weekly isoniazid and rifampin.  In HIV-uninfected patients having no 
cavitation on chest radiograph and negative acid-fast smears at completion of 2 months of 
treatment, the continuation phase may consist of either once weekly isoniazid and rifapentine, or 
daily or twice weekly isoniazid and rifampin, to complete a total of 6 months (bottom).  Patients 
receiving isoniazid and rifapentine, and whose 2-month cultures are positive, should have treatment 
extended by an additional 3 months (total of 9 months). 
* EMB may be discontinued when results of drug susceptibility testing indicate no drug resistance 
† PZA may be discontinued after it has been taken for 2 months (56 doses). 
   RPT should not be used in HIV-infected patients with tuberculosis or in patients with 
extrapulmonary tuberculosis.  
§ Therapy should be extended to 9 months if 2-month culture is positive. 
CXR = chest radiograph; EMB = ethambutol; INH = isoniazid; PZA = pyrazinamide; RIF = rifampin; 
 RPT = rifapentine
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C. Therapy for Patients with Active TB Disease with Drug 
Resistance or Drug Intolerance   
The following medications should only be used in consultation with 
a physician with expertise in the management of drug-resistant TB.  
Table 9.  Second-Line Medications 
Drug Daily Dose     [MAX]




C: Consult expert 
A:750-1000 mg†  
A:400 mg 
Amikacin: IV, IM, 
Kanamycin (KM) IV/IM 
C:15-30 mg/kg/d 







Ethionamide: PO C:15-20 mg/kg 
A:500-1000 mg 
[1gm] 








Clofazimine: PO C:50-200 mg  
A:100-300 mg 
 
Bedaquiline: PO with food C:Not recommended  
A:400 mg daily for 2 weeks, 
then 200mg thrice weeklyƪ 
 
C= Children; A =Adults; * First line medication; can be substituted for EMB 
in initial regimen; † For the treatment of MDR-TB some recommend 1000mg, 
consult an expert for the management of MDR-TB. 
 






Ototoxicity (hearing loss, vestibular dysfunction); renal toxicity 
GI upset; dizziness; hypersensitivity; headaches 
 
Contraindicated in children 
Auditory, vestibular & renal toxicity 
Auditory, vestibular & renal toxicity; hypokolemia; 
hypomagnesemia; eosinophilia 
GI upset; hepatotoxicity; hypothyroidism; metallic taste; 
Bloating 
Psychosis; seizures; headache; depression; other CNS effects (give 50 
mg Vitamin B
6
/250mg of CS) 
GI upset; hypersensitivity; hepatotoxicity; sodium load; drug 
interactions 
Orange/brown skin discoloration; GI complaints 
Nausea, arthralgia, headache † 
American Academy of Pediatrics. Red Book: 2012 Report of the Committee 
on Infectious Diseases. 29th ed. ed. Elk Grove Village, IL: Pickering LK. 
ƪWHO 2013 Interim Policy Guidance; †Package insert, available at: 
http://www.who.int/tb/challenges/mdr/Package_insert_bedaquiline.pdf 
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Note:  In the treatment of drug resistant disease, always use at least 3 
drugs to which the organism is likely to be susceptible.  Never add a 
single drug to a failing regimen.  Intermittent dosing of second-line 
medications is not recommended. 
 
D. Dose Counting  
 Although TB treatment regimens are generally described in 
terms of “months” of treatment, it is important that each 
patient receives an adequate number of doses.  Thus, treatment 
completion is defined by number of doses actually taken as well 
as duration of treatment.  The number of doses required for each 
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Table 10.  First-Line TB Drugs: Dosing for Adults (ages 15 and over) -Directly 
Observed Therapy (DOT) is mandatory 
Drugs 
Adult Dose based on body weight in kilograms (kg)* Adverse 
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Rifapentine Dosed weekly in regimens 1d and 2c (Table 8) 








40-55 kg:1000 mg 
56-75 kg:1500 mg 
>76 kg:2000 mg 
40-55 kg:2000 mg 
56-75 kg:3000 mg 
>76 kg:4000 mg 
40-55 kg:1500 mg 
56-75 kg:2500 mg 








40-55 kg: 800 mg 
56-75 kg: 1200 mg
>76 kg: 1600 mg 
40-55 kg: 2000 mg 
56-75 kg: 2800 mg 
>76 kg: 4000 mg 
40-55 kg: 1200 mg
56-75 kg: 2000 mg
>76 kg: 2400 mg 
Optic neuritis 
*Formula used to convert pounds to kilograms: Divide pounds by 2.2 to get kilograms. 
Example: Patient weighs 154 pounds  2.2 = 70 kilograms.  
 
** Calculate pyrazinamide and ethambutol doses using actual body weight.  Pyrazinamide and 
ethambutol dosage adjustment is needed in patients with estimated creatinine clearance 
less than 50 ml/min or those with end-stage renal disease on dialysis.  
 
NOTE:  Refer to current drug reference or drug package insert for a complete list of adverse drug 
reactions and drug interactions. 
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Table 11.  PEDIATRIC DOSAGE - ISONIAZID IN 







Daily Dose (mg) 
10-15 mg/kg PO 
Twice-weekly 
Dose (mg) 
20-30 mg/kg PO 
6 - 10 3 - 4.5 50 100 mg PO 
11 - 14 5.0 - 6.0 50 150 mg PO 
14.5 - 18 6.5 - 8.0 100 200 mg PO 
18.5 - 21.5 8.5 - 9.5 100 250 mg PO 
22 - 24 10.0 - 11 150 300 mg PO 
25 - 29 11.5 - 13 150 350 mg PO 
29.5 - 32 13.5 - 14.5 200 400 mg PO 
33 - 35 15 - 16 200 450 mg PO 
36 - 40 16.5 - 18. 250 500 mg PO 
40.5 - 43 18.5 - 19.5 250 550 mg PO 
44 - 48 20 - 21.5 300 600 mg PO 
48.5 - 51 22 - 23 300 650 mg PO 
52 - 54.5 23.5 - 24.5 300 700 mg PO 
55 - 57.5 25 - 26 300 750 mg PO 
58 - 62 26.5 - 28 300 800 mg PO 
62.5 - 65 28.5 - 29.5 300 850 mg PO 
>66 >30 300 900 mg PO 
NOTE: Isoniazid tablets are available in 50 mg, 100 mg, 300 mg sizes and 
can be crushed for oral administration.  Isoniazid tablets are also scored. 
Isoniazid Syrup (50mg/5ml) should not be refrigerated.  It contains sorbitol 
and may cause diarrhea.  The isoniazid syrup should only be used when 
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Table 12.  PEDIATRIC DOSAGES - RIFAMPIN IN 
CHILDREN (birth to 14 years) - DOSE for either daily or 
twice weekly therapy 
Child’s Weight 
in lbs Child’s Weight in kg 
Dose (mg) 
10-20 mg/kg 
15 – 32 7 - 14.5 150 
33 - 48.5 15 - 22 300 
49 – 65 22.5 - 29.5 450 
>66  >30  600 
 
 
Table 13.  PEDIATRIC DOSAGES - ETHAMBUTOL IN 
CHILDREN (birth to 14 years) - Ethambutol is available in 
100mg and 400 mg tablets 
Child’s Weight 
in lbs Child’s Weight in kg 
Daily Dose (mg) 
15-25 mg/kg 
11 – 15 5 - 7 100 mg 
16 – 31 8 - 14 200 mg 
32 – 44 15 - 20 300 mg 
45 - 55  21 - 25 400 mg 
56 – 67 26 - 30.5 500 mg 
68 – 76 31 - 34.5 600 mg 
77 – 87 35 - 39.5 700 mg 
88 – 121 40 - 55 800 mg 
122 -165 56 - 75 1200 mg 
>166 >76 1600 mg 
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Table 14: PEDIATRIC DOSAGES PYRAZINAMIDE IN 
CHILDREN (birth to 14 years) - Pyrazinamide is available 







Daily Dose (mg) 
30-40 mg/kg 
Twice Weekly Dose 
(mg) 
50-70 mg/kg 
13 - 23 6 - 10.5 250 mg 500 mg 
24 - 26 11 - 12 250 mg 750 mg 
27 - 31 12.5 - 14 500 mg 1000 mg 
32 - 41 14.5 - 18.5 500 mg 1250 mg 
42 - 47 19.0 - 21.5 750 mg 1250 mg 
48 - 54 22.0 - 24.5 750 mg 1500 mg 
55 - 63 25 - 28.5 1000 mg 1750 mg 
64 - 67  29 - 30.5 1000 mg 2000 mg 
68 - 80 31 - 36.5 1250 mg 2000 mg 
81 - 93 37 - 42.5 1500 mg 2000 mg 
94 - 106 43 - 48.5 1750 mg 2000 mg 
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E. Regimen Options for the Preferred Initial Treatment of 
Children and Adults with Tuberculosis  
1) Initiate therapy with a 4-drug regimen as shown in Table 8.  
For each of the options shown, a TB medical expert should be 
consulted if the patient is symptomatic or is AFB smear or 
culture positive after two months. 
2) For patients with pulmonary tuberculosis, sputum specimens 
should be obtained at least on a monthly basis until two 
consecutive specimens are culture negative (some obtain 
monthly specimens throughout the course of therapy).   
3) For pulmonary TB, obtaining sputum for AFB culture at the time 
of completion of the initial phase (e.g., 2 months) is critical and 
emphasized in order to identify patients at risk for relapse. 
4)  Extended treatment (for 3 additional months for a total of 9 
months) is recommended for patients with drug-susceptible 
pulmonary TB who have cavitary disease on their initial CXR and 
a positive sputum culture after 2 months of therapy.  
5) Twice-weekly therapy in the continuation phase is 
contraindicated for patients with HIV infection who have low 
CD4 counts (<100 cell/µl).  We do not recommend this regimen 
for persons living with HIV, immunocompromising conditions, or 
for those with extrapulmonary or disseminated TB. 
6) Newer rifamycins, rifabutin and rifapentine should be considered 
first-line drugs and can be used in place of rifampin in special 
situations:  rifabutin for patients who are receiving medications, 
especially antiretroviral drugs that have unacceptable interactions 
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with rifampin; and rifapentine along with INH in highly selected 
patients who meet specified criteria in a once-a-week continuation 
phase. 
Rifapentine (RPT): May be used as a primary drug in combination 
with INH in a once-weekly continuation phase for highly-selected 
patients (i.e., HIV seronegative adults, non-cavitary TB) as noted 
in Table 8. This regimen should NOT be used in HIV-
seropositive patients or children.  The weekly dose of rifapentine 
is 10 mg/kg per week [600 mg maximum] plus INH 15 mg/kg per 
week [900 mg maximum]. 
7) Routine follow-up is generally not needed after completion of 
therapy for patients who have had a satisfactory and prompt 
bacteriologic response and who have completed a 6 or 9 months 
of an INH- and RIF-containing regimen. Patients should be 
informed to seek prompt medical evaluation if symptoms 
reappear. Many authorities would continue to follow patients who 
are HIV-infected or who had drug resistant isolates. 
Precautions 
• Daily intake of alcohol increases the risk of hepatitis for patients 
taking INH. 
• The reliability of oral contraceptives is affected in patients being 
treated with RIF.  Alternate contraceptive measures should be 
recommended. 
• RIF will decrease the activity of methadone and a number of other 
drugs (e.g., coumadin, anticonvulsants, fluconazole, protease 
inhibitors).  An increase in methadone (often 50% more) is 
needed to prevent drug withdrawal.  Dosage adjustment of the 
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interacting drugs is recommended. 
• Carefully monitor renal function in patients receiving streptomycin 
(SM), amikacin, kanamycin, or capreomycin. 
• In persons > 60 years of age, the daily dose of SM should be 
limited to 10 mg/kg (max dose = 750 mg). 
• Never add a single drug to a failing regimen.   
• Directly observed therapy (DOT) is the standard of care for 
administering treatment of active TB and such treatment 
should be supervised and coordinated by the local health 
department.  For any patient on self-administered therapy, 
dispense only a 1-month supply of medicine at a time.  
 
F. Drug Resistance 
1. Seek expert consultation for all patients with suspected or 
proven drug-resistant TB. Treatment of TB caused by drug-
resistant organisms should be done by or in close consultation 
with an expert in the management of these difficult situations.  
Second line regimens often represent the patient’s last best 
hope for being cured.  Inappropriate management can have life 
threatening consequences. 
2. Directly observed therapy is the standard of care for all 
patients with drug-resistant TB.   
3. For treatment of suspected or confirmed drug resistant TB, 
select at least three and if possible 4-5 drugs, to which the 
patient has never been exposed and to which the organism is 
known or likely to be susceptible. With suspected or proven 
MDR-TB, regimens which include 4 to 6 drugs are 
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recommended.  A single drug should never be added to a 
failing regimen or to one which has failed in the past.   
Table 15 provides suggestions for potential regimens for the 
treatment of drug resistant TB: 
• For patients with only INH resistance, treat with RIF, PZA, 
EMB for a minimum of 6 months.  A fluoroquinolone is 
sometimes added for extensive disease or in patients who 
cannot tolerate PZA.  If used, susceptibility to the 
fluoroquinolone should be confirmed by drug susceptibility 
testing.   
• For patients with only RIF resistance, treat with INH, EMB, a 
fluoroquinolone and PZA for a minimum of 9-12 months.  An 
injectable agent (e.g., amikacin, kanamycin, streptomycin or 
capreomycin) may be included for the first 2 months of 
treatment for patients with extensive disease. An all oral 
regimen should be given for 12 months. 
• MDR-TB (i.e., resistance to at least INH and RIF) presents 
difficult treatment problems. Treatment must be individualized 
and prolonged, based on medication history and drug 
susceptibility results; seek expert consultation. Regimens are 
often 24 months in duration (at least 12 months after culture 
conversion is documented). Surgery may be beneficial in 
selected patients and improve cure rates for MDR-TB patients 
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INH (± SM) RIF, PZA, EMB (a FQN may 
strengthen the regimen for patients 






RIF INH, EMB, FQN, PZA (an injectable 
agent (IA) may be included for the first 
2 months for patients with more 
extensive disease and/or to shorten 
duration, an injectable agent (Rating 
BIII). An all oral regimen for 12 mo 
should be effective (Rating BIII) 
9-12 
INH, RIF (± 
SM), and 
EMB or PZA 
FQN, (PZA and EMB if active), IA 
(amikacin, kanamycin or 
capreomycin), and at least 2 
alternative agents (e.g., ethionamide 
plus PAS or cycloserine); bedaquiline 
(TMC207) has been FDA approved, 
but its use requires collaboration with 
an expert in the field of MDR-TB* 
24 
Definition of abbreviations: BMRC = British Medical Research Council; 
EMB = ethambutol; FQN = fluoroquinolone; INH = isoniazid; PZA = 
pyrazinamide; RIF = rifampin; SM = streptomycin. FQN = Fluoroquinolone; 
most experience involves ofloxacin, levofloxacin, or ciprofloxacin. Adapted 
from:  MMWR 2003;52(RR-11):1-77  
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In BMRC trials, 6-mo regimens have yielded >95% success rates 
despite resistance to INH if four drugs were used in the initial phase 
and RIF plus EMB or SM was used throughout.  Additional studies 
suggested that results were best if PZA was also used throughout the 
6 mo. Fluoroquinolones were not employed in BMRC studies, but may 
strengthen the regimen for patients with more extensive disease. INH 
should be stopped in cases of INH resistance (see text for discussion). 
Daily and three times weekly regimens of INH, PZA, and SM given for 
9 mo. were effective in a BMRC trial.  However, extended use of an 
injectable agent may not be feasible. It is not known if EMB would be 
as effective as SM in these regimens. An all-oral regimen for 12–18 
mo. should be effective. But for more extensive disease and/or to 
shorten duration (e.g., to 12 months), an injectable agent maybe 
added in the initial 2 mo. of therapy. 
Use the first-line agents to which there is susceptibility.  Add two or 
more alternative agents in case of extensive disease. Surgery should 
be considered (see text). 
 
IA = Injectable agent; may include aminoglycosides (streptomycin, 
amikacin, or kanamycin) or the polypeptide capreomycin. Alternative 
agents = Ethionamide, cycloserine, p-aminosalicylic acid, clarithromycin, 
amoxicillin-clavulanate (Adapted from: MMWR 2003;52:1-77) or linezolid, 
bedaquiline (WHO, 2013 Interim Policy Guidance & Package Insert). 
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       Table 16. ANTITUBERCULOSIS ANTIBIOTICS IN  
Note: Drug adjustments are based on the patient's creatinine clearance 
which can be estimated as follows: 
  (140-age) (Ideal body weight in kg) for men (x 0.85 for women) 
      (72) (serum creatinine, mg/dL)     
Drug Usual Dose (UD) 
Normal Renal Function 
CrCl 25-50 
INH   300 mg/day  UD 
Rifampin 600 mg/d UD 
Ethambutol 15-25 mg/kg/d 15mg/kg/d  
Pyrazinamide 25 mg/kg/d (max 2.0 gm/d) UD 
Levofloxacin 750 mg/d 500 mg/d 
Moxifloxacin 400 mg/d UD  
Ofloxacin 400 mg BID 400 mg/d 
UD = usual dose  CrCl = creatinine clearance (ml/min) 
HD = hemodialysis  d = day 
PD = peritoneal dialysis 
*All four first-line drugs (INH, RIF, PZA, EMB) may be administered thrice 
weekly after HD to facilitate DOT 
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ADULT PATIENTS WITH RENAL IMPAIRMENT 
 
Ideal body weight for men:  50 kg + 2.3 kg per inch over 5 feet 
Ideal body weight for women:  45.5 kg + 2.3 kg per inch over 5 feet 
 
CrCl 10-25 CrCl <10 Hemodialysis* 
Peritoneal 
Dialysis 
UD UD UD UD 
UD UD UD UD 
15 mg/kg q 36° 15 mg/kg q 48° 
15-25 mg/kg 
thrice weekly  
15-25 mg/kg  
thrice weekly  
20 mg/kg/d 
25 mg/kg thrice 
weekly 
25-30 mg/kg thrice 
weekly after HD 
25 mg/kg 
thrice weekly 
250 mg/d 250 mg/d 250 mg/d 250 mg/d 
 UD  UD UD UD 
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G. Monitoring patients on therapy 
1) Response to Treatment 
a. For patients with pulmonary TB, obtain sputum for AFB 
smear and culture at least monthly until two consecutive 
sputum samples are culture negative.  Some authorities 
prefer to obtain monthly AFB sputum smear and cultures 
throughout the course of therapy. 
b. As discussed above, it is essential to obtain a sputum culture 
after two months of therapy to assess risk of relapse. 
c. After two months of therapy, if cultures remain or convert to 
positive or if symptoms do not resolve, obtain new 
specimens for culture and drug susceptibility testing.  Such 
patients should be reviewed for drug resistant disease and 
failure to adhere to the prescribed treatment regimen.  For 
patients receiving self-administered therapy, if cultures do 
not convert to negative after two months of therapy, DOT 
should be initiated. 
d. For patients with drug susceptible TB disease who are 
culture positive after 2 months of therapy and have 
cavitary pulmonary disease on their initial CXR, the 
continuation phase should be increased to 7 months so that 
they receive a total of 9 months of therapy. 
e. Factors to be considered in deciding whether to prolong 
treatment in patients with either cavitation on initial CXR 
or a positive culture after 2 months of therapy (but not 
both) include being more than 10% underweight at 
diagnosis, having HIV infection or having extensive 
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involvement on CXR.   
f. HIV testing should be offered to all persons diagnosed with 
TB. 
g. Given the association between TB and diabetes mellitus the 
point of care hemoglobin A1c test (which was recently 
endorsed by the American Diabetes Association) should 
also be considered for persons diagnosed with active TB.  
2) Monitoring for Adverse Reactions 
a. Obtain the following baseline measurements to detect any 
abnormality that would complicate the regimen or 
necessitate its modification: 
• Hepatic enzyme (e.g., AST or ALT) level, bilirubin, 
serum creatinine, complete blood count, platelet 
count and uric acid level (if PZA is used). 
• Baseline visual acuity (if EMB is used)  
• Baseline audiometry (if SM is used). 
• CD4 count for patients with HIV infection. 
b. Patients with epidemiologic risk factors for hepatitis B or C 
(e.g., injection drug use, birth in Asia or Africa, HIV 
infection) should have serologic tests for these viruses 
performed. 
c. All patients should be seen at least monthly while on therapy 
and questioned about potential adverse reactions.  If 
symptoms suggesting drug toxicity occur, appropriate 
laboratory testing should be performed to confirm or 
exclude such toxicity.  Patients should be instructed to 
report symptoms of hepatitis (which can be induced by 
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INH, RIF and/or PZA) immediately.  Such symptoms 
include nausea, loss of appetite, vomiting, jaundice (dark 
urine, yellow skin), malaise, unexplained fever for > 3 
days, or abdominal tenderness. If patients have jaundice or 
symptoms of liver disease, discontinue medications 
immediately and consult a specialist. 
d. Routine monthly laboratory monitoring is generally not 
required for those being treated for tuberculosis with 
normal baseline and no underlying liver disease. Monitor 
hepatic enzymes (ALT or AST) monthly if baseline levels 
are elevated, and for those with HIV infection, history of 
alcoholism, chronic liver disease, concomitant use of other 
drugs which can cause hepatotoxicity, or pregnancy.  At 
least 20% of patients will have elevated hepatic enzymes; 
asymptomatic elevation less than five times the upper limit 
of normal is not an indication to stop treatment in 
asymptomatic patients.  If patients have jaundice or 
symptomatic liver disease, discontinue medications 
immediately and consult a specialist. 
e. Patients receiving EMB should be questioned regarding 
visual disturbances at monthly intervals; monthly repeat 
testing of visual acuity and color vision is recommended 
for patients receiving an EMB dose exceeding 15-20 
mg/kg (recommended range) and for patients receiving 
EMB for more than two months. 
f. Monitoring tests are frequently required for patients on 
second line drugs (based on the particular drugs being 
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used). 
g.   Pyridoxine will usually prevent INH-induced neurotoxicity 
(peripheral neuropathy).   
h. Hyperuricemia may occur in patients on PZA but acute gout 
is uncommon. Asymptomatic hyperuricemia is not an 
indication for discontinuing the drug. 
i. Drug Interactions: 
• INH and phenytoin (Dilantin) increase the serum 
concentrations of both drugs.  Follow phenytoin levels 
closely. 
• RIF is a potent inducer of both the hepatic and intestinal 
cytochrome P-450 (CYP) enzyme system and P-
glycoprotein (P-gp) transport system, which results in 
numerous clinically significant drug interactions. RIF 
accelerates clearance of a number of drugs metabolized by 
the liver including methadone, coumadin, glucocorticoids, 
estrogens, oral hypoglycemic agents, anticonvulsants, 
fluconazole, voriconazole, itraconazole, cyclosporin, and 
protease inhibitors. 
• Women taking RIF should use a birth control method other 
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H. TB and HIV 
If a patient is infected with M. tuberculosis, HIV infection is a very 
important risk factor for progression to and development of active 
TB disease.  TB is one of the few diseases occurring in HIV-
infected persons that is transmissible, curable and preventable. 
 Persons with HIV infection may have diminished (or absent) 
tuberculin skin test reactions because of immunosuppression.  
Therefore, tuberculin reactions of > 5 mm of induration are 
considered indicative of TB infection in an HIV-infected individual 
(see page 8). 
Because HIV status is a critical factor in the treatment of TB, HIV 
counseling and testing should be offered to all patients with 
active TB disease. 
 The clinical presentation of TB in an HIV-infected person, 
especially those with low CD4 count, may differ from that in 
persons with relatively intact cellular immunity who develop 
reactivation TB.  Apical pulmonary disease with cavitation, a classic 
finding in immunologically competent persons, is less common 
among HIV+ persons, especially among those with low CD4 
counts.  HIV-infected patients may present with infiltrates in any 
lung zone and/or with mediastinal or hilar lymphadenopathy.  
Extrapulmonary and disseminated TB are common among HIV-
infected TB patients.   
1) Treatment for Individuals with TB & HIV 
The treatment of TB in persons with HIV infection is similar to 
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that for patients without HIV infection. There are two 
important exceptions:  1) Once weekly INH-rifapentine in the 
continuation phase should NOT be used in any HIV-infected 
patient; and 2) twice weekly INH-RIF or INH-rifabutin should 
NOT be used for HIV-infected patients with CD4 counts 
<100/µl. In addition, antiretroviral therapy improves outcome 
among patients with TB disease who have HIV co-infection 
and should be initiated as discussed below. 
2) HIV-infected patients with active TB disease should be initiated 
on a 4-drug treatment regimen (INH, RIF [or Rifabutin], PZA 
and EMB) and pyridoxine as outlined in Table 8 on page 40, 
unless contraindications to medication exist. The use of 
antiretroviral therapy and TB medications is discussed on pages 
83-88.  HIV-infected patients with drug-susceptible TB disease 
generally respond well to standard anti-TB drugs.  
3) Patients with HIV co-infection who have drug-susceptible TB 
disease should be treated for a minimum of 6 months with 
anti-tuberculosis therapy.  Duration of therapy should be 
prolonged for patients with delayed or slow response to 
therapy.  HIV infected patients with TB disease should be 
monitored closely for clinical and bacteriological response.  
Prolonged treatment beyond 6 months (e.g., to 9 months) is 
recommended for patients who are slow to respond to therapy, 
including patients who remain culture positive after two 
months of therapy.  Because patient adherence to therapy is 
crucial for good outcomes, DOT is the standard of care and is 
strongly recommended for all HIV-infected patients with active 
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TB.  
4) HIV-infected patients should be monitored very closely during 
therapy as they appear to have a greater frequency of adverse 
reactions to anti-TB drugs. (Obtain a monthly AST or ALT.) 
5) For patients with drug-resistant disease, if both INH and RIF are 
not included in the regimen, treatment should be continued for 
at least 18 months and at least 12 months after culture 
conversion.  Directly observed therapy is essential for all 
patients with MDR-TB.  Seek expert medical advice for all 
patients with MDR-TB. 
6) After treatment is completed, patients should be reminded that if 
symptoms reappear, they should seek prompt medical 
evaluation. 
 
I. Antiretroviral Therapy (ART) and Treatment of HIV  
Seropositive Patients with Active Tuberculosis  Disease.  
 Treatment of HIV-infected patients with active TB disease 
should be carried out in consultation with a physician who has 
experience in the use of rifamycin drugs and antiretroviral 
agents. Recommendations on the treatment of TB in combination 
with antiretroviral therapy continue to evolve and it is important 
to check for updated guidelines. 
(http://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-
adolescent-treatment-guidelines/27/) 
 Antiretroviral therapy (ART) improves outcomes for HIV-infected 
patients and decreases HIV-related mortality, including those with 
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TB disease.  Patients in the United States with tuberculosis disease 
who are HIV-infected should receive treatment for HIV with ART.  
Timing of ART: Several recent studies have demonstrated the 
benefit from early initiation of ART in patients with HIV-TB.  
Patients with TB/HIV had improved survival if ART was started 
during TB therapy rather than at the time of completion of TB 
therapy.  Furthermore, those with TB disease and advanced 
HIV/AIDS with CD4 counts < 50 cells/l3 had improved outcomes 
and survival if ART was started at 2 weeks after initiation of TB 
therapy compared to those who were started on ART at 8 weeks.   
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Table 17.  When to Start HIV therapy 
HHS Panel Recommendations on treatment of Tuberculosis Disease with 
HIV co-infection:  Timing of Antiretroviral Therapy (ART) Initiation relative 
to TB treatment 
CD4 count and/or clinical status  
at time of TB diagnosis 
ART initiation  
 < 50 cells/mm3   within 2 weeks of starting TB 
therapy.   
 > 50 cells/mm3 with 
severe clinical 
disease** 
 within 2 to 4 weeks of 
starting TB therapy 
 > 50 cells/mm3 
without severe 
clinical disease** 
 within 8 to 12 weeks of 
starting TB therapy 
 Pregnant, any CD4 
count 
 As early as feasible 
 MDR or XDR TB, 
any CD4 count 
 Within 2 to 4 weeks of 
confirmation of drug 
resistance and start of second 
line TB therapy 
** severe clinical disease:  low Karnofsky score, low body mass index, low 
hemoglobin, low albumin, organ system dysfunction, or disseminated/widespread 
TB disease 
 
Above based on guidelines developed by the Department of Health and Human 
Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents, 
last reviewed and updated March 27, 2012 (http://aidsinfo.nih.gov/guidelines). 
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Current recommendations are to begin ART at 2 weeks after TB 
diagnosis and initiation of TB therapy for those people living with 
HIV with CD4 counts < 50 cells/l3 (with the exception of those that 
have TB meningitis) and at 8 weeks after initiation of TB therapy for 
all other patients with active TB disease who have HIV co-infection.   
The use of ART among HIV-TB patients is complicated by 
overlapping toxicity profiles of some antituberculosis and 
antiretroviral drugs; complex drug-drug interactions; and the 
occurrence of paradoxical or immune reconstitution reactions 
(termed immune reconstitution inflammatory syndrome [IRIS]).  
Additionally, a study of HIV-TB patients with meningitis found that 
early ART was associated with an increase in severe adverse events 
and no mortality benefit.  Thus, timing of ART initiation in HIV-TB 
patients should take into account both the degree of immune 
suppression and site of disease (see Table 17 for specific 
recommendations).   
Choice of ART:  Because of the potential for significant drug 
interactions and overlapping toxicities, the choice of ART in HIV-TB 
patients should be made only after direct communication between 
HIV and tuberculosis care providers.  Any change in either the TB 
medications or the ART regimen should be immediately shared 
between the 2 providers.   
There are clinically important drug-drug interactions between the 
rifamycins (e.g., rifampin, rifabutin) and some of the antiretroviral 
drugs, especially protease inhibitors.  The rifamycins are inducers of 
the cytochrome P450-3A (CYP3A) system in the liver and thereby 
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decrease serum concentrations of drugs metabolized by this system 
including protease inhibitors.  Rifampin is a potent inducer of the 
CYP3A while rifabutin is a less potent inducer.  Rifampin cannot be 
given with most protease inhibitors because it results in low serum 
levels of these drugs.  Rifabutin has less of an effect and therefore 
can be used with certain protease inhibitors as described below.   
The protease inhibitors also affect rifamycin metabolism and because 
the rifamycin metabolism is retarded by these drugs, the dose of 
rifabutin needs to be reduced in order to avoid rifabutin related 
toxicity.   
Despite these drug-drug interactions, a rifamycin (rifampin or 
rifabutin) should ALWAYS be included in TB regimens for HIV co-
infected patients.  
 
Rifampin can be given with the following antiretrovirals: 
• ALL Nucleoside/nucleotide reverse transcriptase inhibitors 
(NRTIs) (e.g., zidovudine, lamivudine, emtricitabine, 
tenofovir, abacavir).  There are no significant drug 
interactions between the NRTIs and rifampin or other 
rifamycins. 
• SELECTED Non-nucleoside reverse transcriptase inhibitors 
(NNRTIs): efavirenz only (all others are contraindicated for 
co-administration with rifampin). Some clinicians choose to 
increase the dose (from 600mg to 800mg) in patients who 
weigh more than 60 kg but this change in dose is probably 
not necessary.  
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 Integrase inhibitor, raltegravir.  The dose of raltegravir must 
be increased to 800 mg BID for patients on rifampin. 
Rifampin should NOT be used with the following: 
 All protease inhibitors  
 Nevirapine, etravirine, rilpivarine (all NNRTIs) 
 CCR5 antagonist, maraviroc.  
Rifabutin can be substituted for rifampin and used with:  
• Protease inhibitors: atazanavir (with ritonavir boosting), 
darunavir (with ritonavir boosting), fosamprenavir (with 
ritonavir boosting), lopinavir/ritonavir (Kaletra). When 
rifabutin is given in combination with protease inhibitors, 
the dose of rifabutin needs to be reduced as outlined in 
Table 19 (page 78).   
• NRTIs (e.g., e.g., zidovudine, lamivudine, emtricitabine, 
tenofovir, abacavir,).  There are no significant drug 
interactions between the NRTIs and rifamycins. 
• SELECTED NNRTI: efavirenz; the dose of rifabutin should be 
increased to 450 mg daily or 600 mg thrice weekly when 
administered with efavirenz.  
Integrase inhibitor, Raltegravir:  No dose change is needed for 
Rifabutin or Raltegravir when used together.   
 
Rifapentine, a long acting rifamycin, should NOT be used in 
patients with HIV co-infection.  There is a high risk of developing 
rifampin resistance while on TB therapy for HIV-infected persons 
who are treated with rifapentine-based regimens. 
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A summary of preferred treatment options for patients with 
tuberculosis disease who are HIV-infected is shown in Tables 18 and 
19 on pages 76 and 78.  For additional information, please refer to 
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Table 18.  What to start: Choice of TB therapy and 
Antiretroviral Therapy (ART) when treating co-infected patients 
Principle:  Despite drug interactions, a rifamycin (rifampin or rifabutin) 
should be included in TB regimens for patients receiving ART, with dosage 
adjustment if necessary (see Table SMR11 for dosage adjustments). 
Option 1a:  TB regimen: Rifampin-based  
 Preferred ART regimen: Efavirenz (NNRTI) + 2 NRTIs 
(TDF/FTC or ABC/3TC) 
     Contraindicated medications:   
o All PIs  
o Other NNRTIs: Nevaripine, Delviridine, Etravirine, or 
Rilpivirine  
Option 1b: TB regimen: Rifampin-based 
ART regimen: Integrase-inhibitor (RAL) dose-adjusted + 2 NRTIs 
     Preferred ART choices:  RAL + TDF/FTC 
     Alternative ART choices:  RAL + ABC/3TC 
Option 2a: TB regimen: Rifabutin (dose adjusted) substituted for Rifampin 
ART regimen: boosted PI + 2 NRTIs 
     Preferred ART choices:  ATV/r + TDF/FTC 
          DRV/r + TDF/FTC 
    Alternative ART choices:  
 ATV/r + ABC/3TC 
 DRV/r + ABC/3TC 
 FPV/r (once or twice daily) + ABC/3TC or TDF/FTC 
 LPV/r (once or twice daily) + ABC/3TC or TDF/FTC 
Option 2b: TB regimen:  Rifabutin substituted for Rifampin 
ART regimen: Integrase-inhibitor (RAL) usual dose + 2 NRTIs 
     Preferred ART choices:  RAL + TDF/FTC 
     Alternative ART choices:  RAL + ABC/3TC 
 
Choice for Pregnant women with active TB and HIV infection: 
TB regimen: Rifabutin (dose adjusted) substituted for Rifampin 
ART regimen:  LPV/r (twice daily) plus ZDV/3TC 
NRTIs:  nucleoside/-tide reverse transcriptase inhibitors 
NNRTIs:  non-nucleoside reverse transcriptase inhibitors 
PIs: protease inhibitors 
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RAL:  Raltegravir 
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Table 19.  Dosage Adjustments for ART and Rifamycins when 
used in Combination 
 Rifampin (RIF) Rifabutin (RBT) 
NNRTI   
Efavirenz 
(EFV) 
RIF no change (600 mg) 
 
EFV: no change (600 mg qhs) 
*Some clinicians increase EFV 
to 800 mg/d for pts > 60 kg 
RBT: increase to 450 mg/d or 
600 mg/tiw 
 






DO NOT USE RBT: decrease to 150 mg/d or 
300 mg/tiw 
 




RIF: no change (600 mg) 
 
RAL: increase to 800 mg bid 
RBT: no change (300 mg) 
 
RAL: no change (400 mg bid) 
NNRTIs:  non-nucleoside reverse transcriptase inhibitors 
PIs: protease inhibitors 




RAL:  Raltegravir 
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J. Paradoxical Reactions or Immune Reconstitution 
Inflammatory Syndrome (IRIS) Associated with Initiation 
of Antiretroviral Therapy During the Course of TB 
Therapy 
 The temporary exacerbation of TB symptoms and lesions after 
initiation of anti-tuberculosis therapy - known as a paradoxical 
reaction or immune reconstitution inflammatory syndrome (IRIS) - 
has been described as a rare occurrence in HIV-seronegative patients 
after the initiation of anti-tuberculosis therapy. These “paradoxical 
reactions” are thought to be due to immune reconstitution and are not 
uncommon among HIV-infected patients who are started on 
antiretroviral therapy (ART) early in the course of antituberculosis 
therapy. A recent meta-analysis reported that about 16% of patients 
with TB disease and HIV co-infection developed IRIS after starting 
ART and TB IRIS mortality was 3% (Müller et al).  Overall, the 
benefits of early ART, especially among those with advanced 
HIV/AIDS outweigh the adverse effects that can be seen with IRIS.   
Paradoxical reactions or IRIS are characterized by fever, worsening 
infiltrates on chest radiograph, new enlarging and peripheral and/or 
mediastinal adenopathy and cold abscesses, new or worsening CNS 
TB, and new or worsening serositis. The paradoxical reactions are 
associated with increase reactivity on tuberculin skin testing and a 
significant reduction in HIV viral load. Patients with clinical findings 
that are compatible with IRIS should have other diagnoses ruled out. 
These paradoxical or immune reconstitution reactions are usually 
self-limited and can last 10 to 40 days. Mild to moderate reactions 
can be managed by reassurance and non-steroidal anti-inflammatory 
drugs.  Severe reactions included those characterized by marked 
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increase in adenopathy causing an anatomic problem (e.g., 
compromised breathing, swallowing or movement of the neck; or 
expanding central nervous system lesions) can be managed with 
corticosteroids (with continuation of the antituberculosis therapy and 
ART) starting at a dose of prednisone or methyl prednisolone of 1 
mg/kg per day and then tapering the therapy after 1 to 2 weeks of 
therapy.   
 
 K. Treatment of Extrapulmonary Tuberculosis 
 The basic principles that underlie the treatment of pulmonary TB 
also apply to extrapulmonary forms of the disease.  A 6-month course 
of therapy is recommended for treating tuberculosis involving any 
site with the exception of the meninges for which a 9-12 month 
regimen is recommended.  Prolongation of therapy also should be 
considered for patients with tuberculosis in any site that is slow to 
respond.  The addition of corticosteroids is recommended for patients 
with tuberculosis pericarditis and meningitis as it improves outcome 
and decreases mortality as discussed below. 
 Lymphatic and hematogenous TB are especially common among 
persons with HIV infection.  Central nervous system (CNS) 
involvement has been reported and may be difficult to diagnose when 
it occurs in conjunction with other opportunistic CNS infections. 
 To establish the diagnosis of extrapulmonary TB, a variety of 
specimens including pleural fluid, peritoneal fluid, pleural and 
peritoneal biopsy specimens, lymph node tissue, bone marrow, bone, 
blood, urine, brain or cerebrospinal fluid may need to be obtained for 
mycobacterial culture.   
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Specimens must be examined microscopically and sent for AFB 
culture, but the inability to demonstrate AFB on smear and the 
absence of granuloma formation does not exclude the diagnosis of 
TB.  Surgery may be necessary to obtain specimens for diagnosis and 
to treat such processes as constrictive pericarditis or spinal cord 
compression from Pott’s disease (spinal tuberculosis).  Evidence-
based guidelines for the treatment of extrapulmonary TB and 
adjunctive use of corticosteroids are shown in Table 20 page 82. 
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Table 20.  Evidence-based* guidelines for the treatment of extrapulmonary 
tuberculosis and adjunctive use of corticosteroids in patients with drug 
susceptible disease in adults.  






Lymph node 6 AI Not recommended DIII 
Bone and joint 6–9 AI Not recommended DIII 
Pleural disease 6 AII Not recommended DI 
Pericarditis 6 AII Strongly recommended AI 
CNS tuberculosis 
including meningitis 
9–12 BII Strongly recommended AI 
Disseminated 
disease 
6 AII Not recommended DIII 
Genitourinary 6 AII Not recommended DIII 
Peritoneal 6 AII Not recommended DIII 
* For rating system, see Table 3. 
MMWR 2003;52(RR-11):1-77. 
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VI.   Pregnancy 
A. Treatment for LTBI and Risk Factors  
A pregnant woman with a positive skin test (or positive IGRA test) 
and negative chest x-ray (a lead apron should cover the entire 
abdomen during x-ray) should be started on treatment for LTBI with 
INH (300 mg daily) immediately if they have one or more of the 
following risk factors: 
•  Documented recent tuberculin skin test conversion; 
•  HIV infection or those with HIV risk factors who refuse HIV 
testing; 
•  Close contact of patient with AFB smear-positive pulmonary 
TB. 
Pyridoxine (25-50 mg/d) is recommended for all pregnant or 
nursing mothers who receive INH.  All pregnant and immediate 
post-partum patients should have a baseline and monthly AST (or 
ALT) performed while on therapy.  Treatment of other pregnant 
women with a positive diagnostic test for LTBI can be deferred until 
several months after the completion of pregnancy. 
B. Treatment of Active TB in Pregnancy  
 TB disease discovered during pregnancy should be treated without 
delay.  Because of the risk for tuberculosis to the fetus, treatment of 
TB in pregnant women should be initiated whenever the probability 
of maternal disease is moderate to high.  Two or three sputum 
samples should be submitted for examination.  The outcome of the 
cultures and susceptibility test results will determine the regimen for 
continuation of treatment. 
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1)  Drug Treatment in Pregnancy (See Table 21, page 86) 
a) The initial treatment regimen usually consists of INH, RIF and 
EMB; strong consideration should be given to including PZA in 
the initial regimen.   
b) Although detailed teratogenicity data are not available, PZA can 
probably be used safely during pregnancy and is recommended for 
use by the World Health Organization (WHO) and the International 
Union Against Tuberculosis and Lung Disease (IUATLD).  In some 
U.S. jurisdictions, PZA has not been routinely recommended.  PZA 
should be included in the initial regimen for HIV-seropostive 
women and for HIV seronegative women who are thought to be at 
high risk for drug resistant TB.  If PZA is not included in the initial 
treatment regimen, the minimum duration of therapy is 9 months.   
c) Pyridoxine (Vitamin B6) (25 mg/d) is recommended for all 
pregnant women taking INH. 
d) Avoid: Aminoglycosides (e.g., streptomycin, kanamycin, 
amikacin) and capreomycin are contraindicated for all pregnant 
women because of potential adverse effects on the fetus.  
Fluoroquinolones (e.g., levofloxacin, ofloxacin, moxifloxacin, 
gatifloxacin, ciprofloxacin) have been associated with arthropathies 
in young animals; therefore, they should be avoided if possible in 
pregnant women.  Because of lack of data, avoid ethionamide and 
cycloserine in pregnancy.   
 
2)  Breast Feeding 
The small concentrations of first line TB drugs in breast milk do not 
have a toxic effect on nursing new-borns and breast feeding should 
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not be discouraged.  Conversely, drugs in breast milk should not be 
considered to serve as effective treatment for disease or as treatment 
of LTBI in a nursing infant. 
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Table 21.  Use of Anti-TB Medications in Special 
Situations: Pregnancy, Tuberculous Meningitis and Renal 
Failure 





Dosage in Renal 
Insufficiency (3) 
Isoniazid Safe (4) Good (20-100%) No change 
Rifampin Safe (isolated 





Pyrazinamide Caution (1) Good (75-100%) Decrease dose/ 
Increase interval 








Avoid Poor (5) Decrease dose/ 
Increase interval 
(6) 












Ethionamide Do not use Good (100%) No change 




Safe Inflamed meninges 
only (50-100%) 
Incomplete data 
Clofazimine Avoid Unknown Probably no change 
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Safe: Drug has not been demonstrated to have teratogenic effects. 
Avoid: Limited data on safety or for aminoglycosides asssociated with hearing    
impairment and/or other toxicity. 
Do Not Use: Associated with premature labor, congenital malformations or 
teratogenicity. 
NOTES: Table 21: Special Situations 
(1) As with all medications given during pregnancy, anti-TB drugs should be 
used with caution.  The risk of TB to the fetus far outweighs the risk of 
medications.  Pregnant patients with active TB should be treated.  Data are 
limited on the safety of some anti-TB drugs during pregnancy.  Table 21 
presents a consensus of published data and recommendations.  Although 
detailed teratogenic data is not available, PZA can probably be used safely 
for pregnant patients.  Concentrations of anti-TB drugs in breast milk are 
low; treatment with these medications is not a contraindication to 
breastfeeding.  (Conversely, medication present in breast milk is not 
sufficient to prevent or treat TB in the newborn.)  Consult a medical expert 
when treating a pregnant patient who has TB.  For treatment of LTBI, most 
authorities recommend beginning INH several months after delivery, 
unless the woman is at high risk for progression to active TB (e.g., recent 
TST or IGRA conversion, HIV-infected). 
(2) Steroid treatment appears to improve outcome in TB meningitis, particularly 
in patients with altered mental status. 
(3) If possible, monitor serum drug levels of patients with renal insufficiency.  
See pages 60-65 for dosage. 
(4) Supplement with pyridoxine (Vitamin B6) during pregnancy. 
(5) Has been used intrathecally; efficacy not documented. 
(6) Avoid aminoglycosides and capreomycin in patients with reversible renal 
damage, if possible. 
(7) Fluoroquinolones may accumulate in renal failure and are poorly removed by 
dialysis.  Dose adjustment indicated. 
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VII. Childhood Tuberculosis 
The basic principles for treatment of TB disease and infection in 
children and adolescents are essentially the same as adults. The 
objective of treatment is to kill the tuberculous bacilli in the shortest 
amount of time while preventing the development of resistance. 
Dosage adjustments of medications may often be required based on 
weight. When possible, crushed tablets or the mixed contents of 
capsules are preferred over suspensions that may be difficult to 
access and may contain less desirable additives. 
The TST is the most commonly used test for diagnosing LTBI and 
tuberculosis disease in children. Immunologic-based testing 
(IGRA’s) may be used as an alternative to TST placement in 
immune competent children 5 years of age and older to aid in LTBI 
or TB disease diagnosis. The involvement of a provider with 
expertise in management of children with tuberculosis infection or 
disease is beneficial in guiding diagnostic evaluation and treatment.  
 
A. Management Considerations 
1) TB disease in infants and children younger than 4 years of age is 
much more likely to disseminate; therefore, prompt evaluation and 
treatment should be started when the diagnosis is suspected. 
2) As the yield of an organism from sputum specimens in children is 
rare, it may be necessary to rely on the results of cultures and 
susceptibility tests of specimens from the adult source case to guide 
the treatment regimen.  In cases of suspected drug-resistant TB or 
when the M. tuberculosis isolate from the presumed source patient is 
not available, obtaining induced sputa or early morning gastric 
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aspirates may be beneficial. In certain situations, bronchoalveolar 
lavage or tissue biopsy may be considered. 
3) Primary intrathoracic TB (parenchymal infiltration, hilar 
adenopathy, or both, in a child with evidence of tuberculosis 
exposure) should be treated in the same manner as pulmonary TB. 
4) An empiric regimen of four drugs (INH, RIF, PZA, EMB) for 2 
months and RIF and INH for the remaining 4 months when the 
possibility of drug resistance is low is recommended. A three drug 
regimen (INH, RIF, PZA) can be used as initial therapy when the 
isolate (i.e., from source TB case) is known to be fully drug 
susceptible.  Children and adolescents with “adult-type” tuberculosis 
consisting of cavitation and AFB positive sputum samples should 
receive a 4-drug regimen initially until susceptibility is proven. The 
persistence of cavitary lesions and/or the detection of AFB in sputa 
specimens may warrant extension to a 9-month course of therapy.  
When clinical or epidemiologic circumstances suggest an increased 
probability of INH resistance, EMB can be used safely at a dose of 
15-20 mg/kg per day as a fourth drug, even in children too young for 
routine eye testing.  Streptomycin, kanamycin or amikacin can also 
be used as a fourth drug when necessary and may be considered for 
TB meningitis.  
5) In general, extrapulmonary TB, including cervical adenopathy 
(scrofula), can be treated with the same regimen as pulmonary TB 
(i.e., 6 months for drug-susceptible disease).  Exceptions include TB 
meningitis for which 12 months of therapy is currently 
recommended. 
 
90                                                                         GEORGIA TB REFERENCE GUIDE  
6) Directly observed therapy is the standard of care for all 
children. HIV testing should be performed on all individuals 
with TB disease (including children) as the treatment regimen 
(including need for antiretroviral therapy) is altered with HIV 
infection. 
7) Clinical and radiographic examinations may be monitored for 
response to therapy. However, resolution of abnormal findings on 
chest radiography with pulmonary or intrathoracic lymphadenopathy 
may lag behind clinical response. Chest radiography is usually not 
performed at the conclusion of a successful course of treatment and 
should not be used as a criterion for discontinuing anti-TB drugs. 
8) Management of the newborn infant whose mother or other 
caregiver is suspected of having TB is based on individual 
considerations. Separation of the mother (or caregiver) and infant 
should be minimized, if possible. Differing circumstances and 
resulting recommendations are as follows: 
i.  Mother or other caregiver who has a positive tuberculin skin test 
or IGRA and normal chest radiography.  If, after investigation, no 
evidence of active TB disease is found in the mother or caregiver to 
whom the infant is exposed, separation of mother or caregiver and 
infant is not indicated.  These mothers may breastfeed their infants. 
Evaluation of all contacts should be performed to attempt to identify 
a source case. 
ii. Mother or other caregiver who has abnormal chest radiography 
suggestive of tuberculosis disease but is judged to be noninfectious 
at delivery. The situation in which a mother or caregiver’s history, 
physical examination, and sputa examination do not suggest active 
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disease may be considered to be a low risk exposure and the 
separation of mother/ caregiver and the  infant is not necessary. The 
mother/ caregiver should receive therapy and contacts should be 
evaluated with a TST or IGRA to attempt to identify a source case. 
The infant should be followed closely by a pediatric provider.  
iii. Mother who has active TB disease and is suspected of being 
infectious at the time of delivery.  The infant should be assessed for 
evidence of congenital tuberculosis and the mother/caregiver should 
be evaluated for HIV infection. A healthcare provider with expertise 
in the treatment of infants with congenital tuberculosis should be 
consulted to assist with management of the infant’s anti-TB regimen. 
If congenital tuberculosis is not suspected, the infant should receive 
INH (10 mg/kg/ dose) daily until the infant is 3 – 4 months of age 
when a TST should be placed. If the TST result is reactive, an 
evaluation for tuberculosis disease should be conducted. If TB 
disease is excluded, the infant should continue to receive INH until 9 
months of age with monthly assessments to complete treatment for 
LTBI. If the TST at 3–4 months of age is nonreactive and the 
mother/ caregiver’s compliance can be documented, the infant’s INH 
may be discontinued.  
The mother/caregiver and infant should be separated until the 
mother/caregiver and infant have received appropriate 
antituberculosis therapy. The mother/caregiver should wear a mask 
and follow appropriate infection control procedures until she/ he has 
been judged to be noninfectious. The mother/caregiver should be 
separated from the infant in situations where infection with MDR TB 
is possible and/or adherence to therapy cannot be documented. BCG 
immunization may be considered for the infant in these situations. 
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Women with tuberculosis disease who have received 2 weeks of 
appropriate therapy and who are not considered to be contagious 
may breastfeed. A healthcare provider with expertise in tuberculosis 
should be consulted to assist with recommendations in individual 
situations when a women receiving antituberculosis therapy wishes 
to provide human milk to an infant.  
  
 
GEORGIA TB REFERENCE GUIDE 93 
 
VIII. Tuberculosis and Long Term Care Facilities 
TB remains a problem in older individuals who infected many years 
ago and did not develop active disease at the time.  Also, there is 
increasing documentation of outbreaks of TB occurring in nursing 
home residents when a patient with TB disease infects a population 
of older people who are newly exposed to that case. 
 
TB control in nursing homes and long term care facilities must begin 
with a careful assessment of TB status upon admission, including a 
diagnostic test for LTBI (TST or IGRA). For those with a positive 
diagnostic test for LTBI, an assessment and chest x-ray should be 
performed as described above to exclude active TB disease. 
 
Since people over 50 years old may have diminished skin test 
reactivity, the two-step technique (see page 11) of tuberculin skin 
testing is recommended at admission to the nursing home if the TST 
is the diagnostic test being performed to screen for LTBI.  A 
“booster effect” with the TST has been noted in elderly persons in 
whom the delayed type hypersensitivity (DTH) reaction to tuberculin 
may have waned over the years.  In these situations, an initial 
tuberculin skin test may demonstrate a negative reaction but it boosts 
the immune system so that subsequent tuberculin skin tests may be 
increased in size and may be interpreted as positive.  This “boosted” 
response is considered as the valid baseline for the individual and 
thought to represent latent TB infection (after active disease is 
excluded). 
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Residents of nursing homes or long term care facilities whose 
baseline two-step skin tests are negative (or whose baseline IGRA is 
negative if the IGRA is being used to screen for LTBI) on admission 
should have repeat testing performed when an exposure to a case of 
potentially infectious TB has occurred. 
• Any person who converts a TST or IGRA from negative to 
positive should be considered for treatment of LTBI after 
active TB is ruled out (by chest x-ray at a minimum and 
sputum specimens if indicated). 
• Any resident with symptoms of TB regardless of TST (or 
IGRA) results should have a chest x-ray to evaluate for 
active TB disease. 
• Treatment of active TB disease (Class III) is the same as 
that used for younger adults.  
Employees of nursing homes or long term care facilities should have 
two-step tuberculin testing when they start to work in the nursing 
home (if the TST is used for testing of health care workers), and 
annual testing thereafter (if they have not had a TST in the year prior 
to initiating employment).  Employees who are TST (or IGRA) 
positive at baseline should be evaluated for treatment of LTBI (see 
pages 24-30).  Those with recent conversion should be strongly 
encouraged to take treatment for LTBI.  Routine annual symptom 
screening for previously positive TST employees is recommended 
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IX. BCG Vaccination 
Bacille Calmette-Guerin (BCG) vaccine is one of the most 
commonly used vaccines in the world and is given in the vast 
majority of low and middle income countries.  BCG is recommended 
in higher TB prevalence areas because it has a documented 
protective effect against TB meningitis and disseminated TB in 
children. It does not prevent primary infection and, more 
importantly, does not prevent reactivation of latent pulmonary 
infection, the principal source of bacillary spread in the community. 
The impact of BCG vaccination on transmission of M. tuberculosis 
is therefore very limited (or there is no impact).  BCG has not 
impacted the global epidemiology of TB.  Because of variable 
efficacy, BCG is NOT recommended in the U.S.  BCG is not a 
contraindication to a TST but as noted there can be cross reactions 
between BCG and the TST.  The primary advantage of IGRAs is that 
they do not cross react with BCG.  Interpretation of a tuberculin skin 
test reaction is not changed for patients who have received BCG.  A 
reaction of >10 mm (> 5mm in HIV-infected persons) of induration 
should be considered infection with M. tuberculosis because: 
• Conversion rates after BCG vaccination are not 100%; 
• The mean reaction size among BCG vaccinees is often less than 
10 mm (a large reaction is more likely to be due to infection 
with M. tuberculosis than BCG vaccination); 
• Tuberculin sensitivity tends to wane considerably after BCG 
vaccination; and, 
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• BCG is often given in areas where TB is endemic, so assume 
that the reaction is from infection, not vaccination. 
 
 Since many BCG-vaccinated persons come from areas of high TB 
prevalence, it is important that persons with a positive TST be 
evaluated for presence of TB disease and managed accordingly.  
Appropriate follow-up includes a careful medical history, CXR to 
rule out active TB disease, and evaluation for treatment of LTBI.  An 
IGRA is the preferred LTBI test among individuals with a history of 
BCG vaccination but a TST is an acceptable test in BCG-vaccinated 
persons.   
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X. TB Infection Control:  Hospital Isolation 
Procedures 
Effective infection control efforts are essential in preventing 
nosocomial transmission of TB.  A hierarchy of control measures is 
recommended to prevent TB transmission in health care facilities. 
A.  Administrative Controls 
Administrative controls are most important and include measures to 
reduce the risk of exposure to persons with infectious TB; this 
includes careful screening, early identification and treatment of 
patients with TB.  A high index of suspicion is critical.  Patients with 
or at risk for TB need to be isolated upon admission (placed in a 
negative pressure airborne infection isolation [AII] room).  
Unsuspected patients with active TB disease and misdiagnosis 
(especially among HIV-infected patients who may have “atypical” or 
non-classical presentations) have led to nosocomial transmission at a 
number of hospitals (as well as at correctional institutions and other 
health care facilities). 
Grady Memorial Hospital in Atlanta has prevented nosocomial 
transmission in large part by the effective use of administrative 
controls.  Careful screening of patients and isolation of those at risk 
for TB have been accomplished by the introduction of an expanded 
respiratory isolation policy.  
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B.  Surveillance for Health Care Workers  
All health care workers should have baseline test for LTBI (unless 
documented to be previously TST positive) and at intervals 
determined by their risk of exposure.  Two-step tuberculin skin 
testing upon employment is recommended unless the HCW had a 
TST in the prior year. For serial testing of HCWs, we recommend 
the use of the TST rather than an IGRA for reasons described above 
(Section IX). The frequency of tuberculin skin testing (or IGRA if 
that is used) is determined by the risk assessment.  For healthcare 
workers in medium risk settings (i.e., institutions with ≥ 200 beds 
and 6 or more TB cases per year or < 200 beds and ≥ 3 TB cases per 
year), testing should be done annually.  For low risk settings (i.e., ≥ 
200 beds and less than 6 TB cases or < 200 beds and < 3 TB cases 
per year), testing of healthcare workers should be done at baseline 
and then only if an exposure occurs but not on a routine basis.  TB 
clinics and TB outreach programs should be considered medium 
risk.  Any inpatient or outpatient setting with evidence of recent 
patient to patient or patient to healthcare worker transmission of M. 
tuberculosis should be classified as potential ongoing transmission 
until appropriate control measures have been implemented and 
transmission ceases.  This is a temporary classification which 
requires immediate interventions; healthcare workers in such settings 
should be tested for LTBI every 3 months until transmission has 
been terminated. 
Any worker who develops symptoms of active TB disease or whose 
test for LTBI (TST or IGRA) converts to positive should be 
evaluated promptly.  Health care workers with recent TB infection 
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on the basis of a conversion to a positive test for LTBI (regardless of 
age) and no evidence of active disease should be encouraged to take 
treatment for LTBI (see pages 24-34).  Health care workers should 
be educated about the basic concepts of TB transmission and 
pathogenesis, infection control practices, and the signs and 
symptoms of TB.  
Grady Hospital TB Isolation Policy 
   Criteria for Isolation Length of Isolation 
1.  Active Pulmonary 
TB 
Duration of hospitalization if less than 
4 weeks; if >4 weeks must have 
clinical response, drug susceptibility 
data and 2 negative AFB sputum 
smears 
 
2.  “Rule Out” TB 
Any patient who has 
sputum for AFB 
collected or pulmonary 
TB is in the differential 
diagnosis. 
 
Until 2 sputum AFB smears are 
negative 
3.  HIV+ patient 
admitted  
with abnormal CXR 
Until 2 sputum AFB smears are 
negative 
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C. Environmental Controls 
Patients admitted to health care facilities with suspected or 
confirmed TB should be placed in an airborne infection isolation 
(AII) room (i.e., negative pressure rooms with > 6 air changes per 
hour; > 12 for new construction); air from AII rooms should be 
exhausted directly to the outside or through a HEPA filter before 
being recirculated. 
 
D. Personal Respiratory Protection 
Appropriate respirator masks should be worn by health care workers 
when entering AII rooms or performing high risk procedures such as 
cough inductions and bronchoscopy.  Use of a N-95 respirator by 




GEORGIA TB REFERENCE GUIDE 101 
 
XI. Community Tuberculosis Control  
A.    Reporting Requirements 
  • In Georgia, the law requires all TB cases must be reported to 
the local county public health department.  This is the 
responsibility of the physician.  At Grady Memorial 
Hospital, the TB Control Coordinator in the Epidemiology 
Department (404-616-3598) reports all patients with active 
disease to the local health departments for the physician.  
Any health care provider who is managing TB patients in 
non-health department settings must update the health 
department on the progress of each patient, including 
sputum results on a quarterly basis.  Cases may be 
reported electronically at http://sendss.state.ga.us, by 
calling 1-866-782-4584, or by calling your local health 
department. 
  • Addition reporting requirements   
ALL Latent TB infection (LTBI) in children under 5 
years of age must be reported to the patient's local county 
public health department. 
A Source Case Investigation should be conducted by the 
health department when LTBI is found in a child under 5 
years old.  
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B. Role of the Health Department 
Health department staff are trained and experienced in contact 
investigation, provision of directly observed treatment of latent TB 
infection (LTBI) and directly observed therapy (DOT) for the 
treatment of patients with active disease.  DOT is the standard of 
care for all patients with TB disease in Georgia and is strongly 
recommended for all patients with tuberculosis to facilitate 
















Role of the Health Department 
• Identify and treat all persons with TB disease; 
ensure that patients complete appropriate therapy 
 
• Provide Directly Observed Therapy (DOT) 
 
• Provide laboratory services 
 
• Identify and evaluate contacts to persons with 
infectious TB; offer therapy as appropriate 
 
• Screen high-risk groups for TB infection; offer 
therapy as appropriate 
 
• Collect and analyze data 
 
• Provide training, education, and consultation 
testing should be only one test. 
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Early reporting of suspected or confirmed TB cases is important for 
control of TB and it gives the clinician access to the resources of the 
public health department for assistance in case management and 
contact investigation.  Contact investigations are indicated to 
determine those who have been exposed to infectious TB patients so 
tuberculin skin testing can be performed on close contacts and 
treatment of LTBI can be initiated for those who have been infected. 
 Tuberculosis services (radiology, medical consultations, DOT, etc.) 
are available in every health district.  All TB medications are 
provided by the state pharmacy free of charge. 
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C. Grady Hospital TB Discharge Policy  
For TB control efforts, it is important that there be a smooth 
transition from the in-patient to the out-patient setting and close 
cooperation and coordination of activities among the wide variety of 
organizations involved in TB patient care, education and TB 
control. 
  To improve TB control efforts in Atlanta and protect the 
community from TB, a TB Discharge Policy has been developed for 
Grady Memorial Hospital.  The standard requires that:  
•  Patients be discharged on an appropriate anti-TB regimen 
(e.g., 4 drug regimen) 
•  All TB patients have their discharge endorsed in the chart 
prior to discharge by the Hospital’s TB social worker and 
the local health department liaison;  
•  All TB patients meet appropriate criteria for discharge 








Summary:   
Grady Hospital TB Discharge Policy 
Site & Patient  
Characteristics 
Criteria 
I.  Another Acute Care 
 Hospital  
Transfer anytime when stable 
II. Prison with Appropriate   
Isolation  
Transfer when medically ready for 
discharge unless MDR-TB 
suspected 
III. American Lung 
Association  (ALA) 
Alternative Housing  
 Program 
 (GA DPH/ALAG) 
 
Transfer when medically ready for 
discharge 
IV. Home When medically ready for 
discharge AND the criteria shown 
















Unstable Home or 
Prison 
Need A, B, C, D, H 
 
Cannot discharge to 
these sites 
Cavitary or moderate 
infiltrate and/or positive 





Need A, B, C, H 
 
Need C, E, F, I or 
Need C, E, F, G 
Minimal or no infiltrate & 
initial AFB respiratory 




Need A, B, & C 
 
Need C, E, & F 
Non-respiratory TB closed 





Need A, B, & C 
 
Need C, E, & F 
Non-respiratory TB open 




Need, A, B, C, D 
 
Need C, D, E, & F 
Positive AFB smear now; 
previous positive culture 
for non-TB Mycobacteria 




Need A, B, C, D, H 
 
Need C, D, E, & F 





Need A, B, C, & D 
 
Need C, D, E, & F 
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Keys to Letters Defining Criteria: 
A. Social service and county health department liaison have documented 
stable/appropriate home environment. 
B. Arrangement is made and documented in the chart for follow-up visit by 
appropriate county health dept, clinic or other appropriate health care 
provider, as soon as possible and no longer than 10 week days after 
discharge.  Patient (and/or family and/or significant other) are informed 
of arrangement. 
C. Patient (and/or family and/or significant other) has received discharge 
teaching about the disease and about isolation, if appropriate. 
D. Pulmonary or infectious diseases consult or hospital epidemiologist 
endorses in chart that disposition is appropriate. 
E. Social service and the county health liaison document unstable home 
environment. 
F. Patient has arrangement made and documented in chart for follow-up visit 
by county health dept, clinic or other appropriate health care provider, as 
soon as possible (no longer than 5 week days after discharge).  Patient, 
family and/or significant other are informed of arrangement. 
G. After 2 negative AFB smears. 
H. Patient has good clinical response to initial anti-TB therapy and when 
medically stable:  there will be no new persons exposed to the patient in 
the home who have not been in long-term contact with the patient prior 
to hospitalization; patient (and family or significant others, as applicable) 
agrees to and is assessed as likely to comply with isolation of the patient 
at home, until the patient is seen by the county health department 
I. Patient accepted into American Lung Association (ALA) Alternative 
Housing Program. 
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D. The U.S.-Mexico Binational Tuberculosis Referral 
Program (CureTB) 
CureTB (www.curetb.org) is part of the San Diego County Public 
Health Services TB Control Branch a referral and continuity of care 
program for tuberculosis patients and their contacts who travel 
between the United States and Mexico. Services are available for 
patients, their families and providers from any state in the United 
States or Mexico. CureTB also provides services for patients 
travelling to other countries. 
CureTB facilitates and supports continuity of care for individuals 
with active tuberculosis disease and their contacts, and provides 
linkages to ongoing care and follow-up for all referred patients.  
CureTB accepts referrals from health departments, correctional 
facilities, and other entities that diagnose or treat patients with 
tuberculosis. 
The Binational Card is a tool to help mobile patients and their 
families connect with CureTB when they arrive at their next 
destination. They can also give the card to their provider to connect 
with CureTB to obtain the latest clinical information. The card is 
easy to carry and has the CureTB 1-800 number, reachable from 
inside or outside the US. 
To request binational cards 
 Telephone: (619) 542-4013  
 e-mail: curetb.hhsa@sdcounty.ca.gov  
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CureTB accepts referrals for  
 Persons with active Tuberculosis and those suspected 
of having TB 
 Contact Notification 
 Source Case Finding 
 Clinical History Request 
 
To Submit a CureTB Referral  
You can submit a CureTB referral in three ways.  Use a referral 
form and attach hard copies of relevant clinical information 
whenever possible.  Visit the www.curetb.org website for additional 
information regarding the relevant clinical information for the 
different types of referral. 
 
1.  Fax: (619) 692-8020 
2.  E-mail:curetb.hhsa@sdcounty.ca.gov  
3.  Call: (619) 542-4013 
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XII. Georgia Department of Public Health (DPH) 
Community Guidelines for Respiratory Isolation of 
Patients with Active TB in the Community  
In setting guidelines, the Georgia Department of Public Health 
(DPH) follows CDC recommendations that a stepwise approach be 
used to seek the least intrusive policy that is consistent with 
maintaining the health of the community.  These guidelines provide 
a framework for clinical management of TB patients.  The 
management of each patient must be customized to the individual’s 
circumstances, living environment, and compliance with TB therapy.  
The guidelines classify active TB cases into three grades of 
infectiousness and two grades of organism resistance.  They 
recommend appropriate levels of housing options and degrees of 
respiratory isolation for each grade of infectiousness and resistance. 
Infectiousness is graded by AFB smear, TB culture results, clinical 
improvement in response to medical therapy, and evidence of 
adherence with therapy. 
 
Grades of Infectiousness: 
Grade I: smear positive, culture positive 
Grade II: smear negative, culture positive or unknown 
Grade III: smear negative, culture negative 
Smear negative = three consecutive negative sputum 
AFB smears on separate days. 
Culture negative = three consecutive negative AFB 
cultures one week apart. 
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Drug susceptibility or drug resistance is based on the drug 
susceptibility testing results on the M. tuberculosis isolate recovered 
from the patient.  TB isolates are considered fully susceptible if they 
have been shown to be susceptible to all first line anti-TB drugs.  
Resistant strains are those resistant to one or more anti-TB drugs. 
 
Housing options include home for patients who can return to a stable 
home and three levels of facilities for those without a stable home. 
Levels of housing: 
Level 1: Acute care hospital 
Alternative Housing Program (smear positive, 
medically stable and clinical improving) 
Level 2: Shelters that require negative smears; trained staff 
provide DOT, Alternative Housing Program (smear 
positive, medically stable and clinical improving) 
Level 3: Shelters that require negative cultures; trained staff for 
DOT available  
These categories of respiratory isolation, based on guidelines from 
the National Jewish Center for Immunology and Respiratory 
Disease, regulate patient activities and use of masks based on grade 
of infectiousness: 
A) Activity defined by the Level 1 institution; 
B) Home permitted provided that no new persons will be 
exposed in the home; 
C) Wear mask to medical appointments, otherwise stay home; 
D) Wear mask only when indoors around unexposed persons. 
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Per CDC guidelines, use simple surgical masks for patients. Isolation 
categories apply to patients with clinical improvement in response to 
medical therapy (e.g., resolution of fever, diminished cough, reduced 
number of organisms on AFB smear) and evidence of adherence 
with therapy.  DOT is the standard of care for all TB patients in 
Georgia. 
 
 Patients must cover all coughs or sneezes with double tissues and 
dispose of the tissues directly into the toilet or into a paper or plastic 
bag before putting them in the trash. 
 
All high risk contacts (i.e. immunocompromised individuals, inmates 
of correctional facilities, residents of long term care facilities, 
IVDUs, close contacts, children < 5 years of age) should be placed 
on treatment for latent TB infection for three months, unless 
otherwise contraindicated, regardless of results of skin testing (or 
IGRA test) and in the presence of a normal chest x-ray (if abnormal 
patient should be evaluated for active TB disease).  If initial TST (or 
IGRA) is negative, the test should be repeated in three months. 
 
NOTE: If patient is high risk for MDR-TB, manage as drug-resistant 
until susceptibility results are available and isolate is known to be 
drug susceptible.  If at low risk for MDR-TB and clinically 
improving, patient can be managed with restrictions as for drug 
susceptible disease. 
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811 Hemlock St 









Ketty M. Gonzalez, M.D., 
M.S. 
East Central Health 
District (Augusta) 
District 6 
1916 N Leg Rd 
Augusta GA 30909-4437 
T: 706-667-4250 
F: 706-667-4365 
kmgonzalez@dhr.state.ga.us   
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Beverley A. Townsend, 
M.D., MBA 
West Central Health 
District (Columbus) 
District 7 
PO Box 2299 
Columbus GA  31902-2299 
T: 706-321-6300 
F: 706-321-6126 
batownsend@dhr.state.ga.us   
AA:  Carol Popwell  
T : 706-321-6108 
 
 
William R. Grow, M.D., 
FACP 
South Health District 
(Valdosta) 
District 8, Unit 1 
PO Box 5147 











Jacqueline H. Grant, 
M.D., MPA, MPH 
Southwest Health District 
(Albany) 
District 8, Unit 2 
1109 N. Jackson St 








Diane Z. Weems,  M.D. 
(Interim) 
Coastal Health District 
(Savannah/Brunswick) 
District 9, Unit 1 
1395 Eisenhower Drive 
Savannah GA  31406 
T: 912-356-2897   
C : 912-657-4629 
F: 912-356-2868 
dzweems@dhr.state.ga.us  
AA: Ruthie Smoak   
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Rosemarie D. Parks, 
M.D., MPH 
Southeast Health District 
(Waycross) 
District 9, Unit 2 
1101 Church St 




AA:  Melinda Monroe   
T : 912-285-6020 
 
 
Claude A. Burnett, M.D., 
MPH 
Northeast Health District 
(Athens) 
District 10 
220 Research Dr 




AA:  Linda McGinnis  
T : 706-583-2870 
Georgia Department of 
Public Health 
Division of Health 
Protection 
2 Peachtree Street, N.W., 
Atlanta, Georgia 30303 
404-657-2634 
 
 
  
